10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q/A

Amendment No. 1

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _____________ to ___________________

Commission File Number 000-54365

BRAINSTORM CELL THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware	20-8133057
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

605 Third Avenue, 34th Floor

New York, NY 10158

(Address of principal executive offices)

(646) 666-3188

(Registrant's telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x   No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨ (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of August 10, 2012, the number of shares outstanding of the registrant’s common stock, $0.00005 par value per share, was 148,405,612.

Explanatory Note

The purpose of this Amendment No. 1 to our Quarterly Report on Form 10-Q for the period ended June 30, 2012, as filed with the Securities and Exchange Commission on August 13, 2012 (the “Form 10-Q”), is to furnish Exhibit 101 XBRL (eXtensible Business Reporting Language) interactive data files within the 30-day grace period provided by Rule 405 of Regulation S-T applicable for the first quarterly period in which detailed footnote tagging is required.

No other changes have been made to the Form 10-Q.  This Form 10-Q/A speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the Form 10-Q.

Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

Item 6. Exhibits.

Exhibit Number	Description
4.1	Form of Warrant, incorporated herein by reference to Annex B of the Company’s Rule 424(b)(1) Prospectus filed July 19, 2012 (File No. 333-179331).
10.1	Brainstorm Cell Therapeutics Inc. Amended and Restated 2004 Global Share Option Plan is incorporated herein by reference to Exhibit A to the Registrant’s Definitive Schedule 14A filed May 7, 2012 (File No. 000-54365).
10.2	Brainstorm Cell Therapeutics Inc. Amended and Restated 2005 U.S. Stock Option and Incentive Plan is incorporated herein by reference to Exhibit B to the Registrant’s Definitive Schedule 14A filed May 7, 2012 (File No. 000-54365).
10.3	Form of Securities Purchase Agreement, incorporated herein by reference to Annex A of the Company’s Rule 424(b)(1) Prospectus filed July 19, 2012 (File No. 333-179331).
10.4	Form of Placement Agency Agreement by and between Brainstorm Cell Therapeutics Inc. and Maxim Group LLC, incorporated herein by reference to Exhibit 10.58 of the Company’s Registration Statement filed June 29, 2012 (File No. 333-179331).
10.5	Form of Common Stock Purchase Warrant issued by Brainstorm Cell Therapeutics Inc. to Placement Agent, incorporated herein by reference to Exhibit A of Exhibit 10.58 of the Company’s Registration Statement filed June 29, 2012 (File No. 333-179331).
10.6	Consulting Agreement, dated as of May 31, 2012, by and between Brainstorm Cell Therapeutics Inc. and Dr. Daniel Offen, incorporated herein by reference to Exhibit 10.15 of the Company’s Registration Statement filed June 29, 2012 (File No. 333-179331).
31.1	Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2	Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1	Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.2	Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

101.INS	XBRL INSTANCE DOCUMENT
101.SCH	XBRL TAXONOMY EXTENSION SCHEMA
101.CAL	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
101.DEF	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
101.LAB	XBRL TAXONOMY EXTENSION LABEL LINKBASE
101.PRE	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

* Previously filed as an exhibit to the Registrant's Form 10-Q for the quarter ended June 30, 2012, filed with the Securities and Exchange Commission on August 13, 2012.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BRAINSTORM CELL THERAPEUTICS INC.
August 29, 2012	By:	/s/ Adrian Harel
		Name: Adrian Harel
		Title: Chief Executive Officer (Principal Executive Officer)

August 29, 2012	By:	/s/ Liat Sossover
		Name: Liat Sossover
		Title: Chief Financial Officer (Principal Financial Officer)

XML

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2012

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies [Text Block]

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2011 are applied consistently in these financial statements.

XML

GENERAL

6 Months Ended

Jun. 30, 2012

General and Going Concern Disclosure [Abstract]

Business Description and Basis of Presentation [Text Block]

NOTE 1 - GENERAL

A. Brainstorm Cell Therapeutics Inc. (formerly: Golden Hand Resources Inc.) (the "Company") was incorporated in the State of Washington on September 22, 2000.

B. On May 21, 2004, the former major stockholders of the Company entered into a purchase agreement with a group of private investors, who purchased from the former major stockholders 6,880,000 shares of the then issued and outstanding 10,238,000 shares of Common Stock.

C. On July 8, 2004, the Company entered into a licensing agreement with Ramot of Tel Aviv University Ltd. ("Ramot"), to acquire a license certain stem cell technology (see Note 3). Subsequent to this agreement, the Company decided to focus on the development of novel cell therapies for neurodegenerative diseases, based on the acquired technology and research to be conducted and funded by the Company.

Following the licensing agreement dated July 8, 2004, the management of the Company decided to abandon all old activities related to the sale of the digital data recorder product. The discontinuation of this activity was accounted for under the provision of Statement of Financial Accounting Standard ASC 360-10 (formerly "SFAS" 144), "Accounting for the Impairment or Disposal of Long-Lived Assets".

D. On October 25, 2004, the Company formed a wholly-owned subsidiary in Israel, Brainstorm Cell Therapeutics Ltd. ("BCT").

E. On November 22, 2004, the Company changed its name from Golden Hand Resources Inc. to Brainstorm Cell Therapeutics Inc. to better reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. BCT, as defined above, owns all operational property and equipment.

F. On September 17, 2006, the Company's changed its fiscal year-end from June 30 to December 31.

G. In December 2006, the Company changed its state of incorporation from Washington to Delaware.

H. Since inception, the Company has devoted substantially all of its efforts to research and development, recruiting management and technical staff, acquiring assets and raising capital. In addition, the Company has not generated revenues. Accordingly, the Company is considered to be in the development stage, as defined in Statement of Financial Accounting Standards No. 7, "Accounting and reporting by development Stage Enterprises" ASC 915-10 (formerly "SFAS" 7).

I. In October 2010, the Israeli Ministry of Health granted clearance for a Phase I/II clinical trial using the Company’s autologous NurOwn™ stem cell therapy in patients with amyotrophic lateral sclerosis (“ALS”), subject to some additional process specifications as well as completion of the sterility validation study for tests performed.

On February 23, 2011, the Company submitted, to the Israel Ministry of Health (MOH), all the required documents. Following approval of the MOH, a Phase I/II clinical study for ALS patients using the Company’s autologous NurOwn™ stem cell therapy was initiated in June 2011.

J. In February 2011, the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation to the Company’s NurOwn™ autologous adult stem cell product candidate for the treatment of ALS.

GOING CONCERN

As reflected in the accompanying financial statements, the Company’s operations for the six months ended June 30, 2012, resulted in a net loss of $1,702. The Company’s balance sheet reflects an accumulated deficit of $45,780. These conditions, together with the fact that the Company is a development stage Company and has no revenues nor are revenues expected in the near future, raise substantial doubt about the Company's ability to continue to operate as a going concern. The Company’s ability to continue operating as a “going concern” is dependent on several factors, among them is its ability to raise sufficient additional working capital.

In 2009, the Company decided to focus only on the effort to commence clinical trials for ALS and such trials did commence in 2011.

Following the balance sheet date, in July 2012, the Company raised $4.9 million, net, in a public offering. (See Note 7) However, there can be no assurance that additional funds will be available on terms acceptable to the Company, or at all.

These financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

XML

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011
ASSETS
Cash and cash equivalents	$ 843	$ 1,923
Accounts receivable	421	312
Prepaid expenses	137	69
Total current assets	1,401	2,304
Long-Term Investments:
Prepaid expenses	17	17
Severance payment fund	134	109
Total long-term investments	151	126
Property and Equipment, Net	298	314
Total assets	1,850	2,744
LIABILITIES AND STOCKHOLDERS' EQUITY
Trade payables	515	244
Accrued expenses`	790	750
Other accounts payable	145	141
Total current liabilities	1,450	1,135
Accrued Severance Pay	147	121
Total liabilities	1,597	1,256
Commitments And Contingencies Stockholders' Equity:
Stockholders' Equity:
Stock capital: (Note 6) Common stock of $0.00005 par value - Authorized: 800,000,000 shares at June 30, 2012 and December 31, 2011; Issued and outstanding: 128,586,644 and 126,444,309 shares at June 30, 2012 and December 31, 2011 respectively.	6	6
Additional paid-in-capital	46,027	45,560
Deficit accumulated during the development stage	(45,780)	(44,078)
Total stockholders' equity	253	1,488
Total liabilities and stockholders' equity	$ 1,850	$ 2,744

XML

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) [Parenthetical] (USD $) In Thousands, except Per Share data, unless otherwise specified	6 Months Ended	12 Months Ended
	Mar. 31, 2001	Dec. 31, 2010	Dec. 31, 2008	Dec. 31, 2007	Mar. 31, 2006	Mar. 31, 2005	Mar. 31, 2004
Price per share of stock issued on September for cash	$ 0.00188
Price per share of stock issued on March for cash	$ 0.0375
Price per share of stock issued to purchase mineral option							$ 0.065
Price per share of stock issued On June for private placement						$ 0.01
Stock issuance expenses (in dollars)						$ 25,000
Price per share of stock issued for private placement			$ 0.1818	$ 0.1818		$ 0.75
Price per share of stock issued On May for private placement					$ 0.80
Price per share of stock issued On July for private placement					$ 0.60
Price per share of stock issued On September for private placement					$ 0.80
Price per share of stock issued On December for private placement					$ 0.80
Price per share of subscription of shares for private placement		$ 0.12	$ 0.1818

XML

STOCK CAPITAL (Details 3) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended		141 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012
Total stock-based compensation expense	$ 140	$ 658	$ 313	$ 443	$ 7,134	[1]
Research and Development Expense [Member]
Total stock-based compensation expense	12	10	25	19	17,581
General and Administrative Expense [Member]
Total stock-based compensation expense	128	456	296	454	10,409
Interest Expenses [Member]
Total stock-based compensation expense	$ 0	$ 192	$ 0	$ 192	$ 248

[1] Out of the which, cash flows used in discontinued operating activities of $36, cash flows used in discontinued investing activities of $16 and cash flows provided in discontinued financing activities of $57, relating to the period from inception to March 31, 2004, is unaudited.

XML

SUBSEQUENT EVENTS (Details Textual) (USD $)	1 Months Ended				12 Months Ended				1 Months Ended												2 Months Ended	6 Months Ended	12 Months Ended
	Jul. 17, 2012	Jul. 31, 2012	Jun. 30, 2011	Jan. 31, 2011	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2004	Jun. 30, 2012	Mar. 31, 2011 Private Placement [Member]	Feb. 28, 2011 Private Placement [Member]	Jan. 31, 2011 Private Placement [Member]	Feb. 28, 2010 Private Placement [Member]	Jan. 31, 2010 Private Placement [Member]	Aug. 31, 2009 Private Placement [Member]	Dec. 31, 2005 Private Placement [Member]	Aug. 31, 2005 Private Placement [Member]	Jul. 31, 2005 Private Placement [Member]	May 31, 2005 Private Placement [Member]	Mar. 31, 2005 Private Placement [Member]	Feb. 28, 2005 Private Placement [Member]	Aug. 17, 2012 Private Placement [Member]	Jun. 30, 2012 Private Placement [Member]	Dec. 31, 2004 Private Placement [Member]
Proceeds From Issuance Of Common Stock Gross	$ 5,700,000									$ 250,000		$ 1,500,000	$ 250,000		$ 135,000		$ 99,000	$ 149,000	$ 225,000	$ 1,418,000			$ 60,000
Stock Issued During Period, Shares, New Issues			476,666		309,977				41,666,667	833,333	10,499,999	6,000,000		9,916,667			165,000	186,875			19,818,972		8,510,000
Common Stock, Par Or Stated Value Per Share					$ 0.00005			$ 0.00005
Exercise Of Warrants, Conditions	warrants to purchase 0.75 shares of Common Stock for every share purchased in the Public Offering, at an exercise price of $0.29 per share
Stock Issued During Period, Value, New Issues	4,900,000			235,000		400,000
Percentage Of Cash Fee On Gross Proceeds Of Offering		6.00%
Percentage Of Corporate Finance Fee On Gross Proceeds Of Offering		1.00%
Placement Agent Fees And Expenses		$ 100,000
Warrants Issued To Placement Agent For Purchase Of Common Stock	19,818,972	594,569
Percentage Of Warrants Issued Out Of Shares Issued In Public Offering		3.00%
Investment Warrants, Exercise Price		$ 0.348					$ 0.01			$ 0.39	$ 0.2	$ 0.5	$ 0.5			$ 1				$ 2.5		$ 0.348
Premium On Warrant Exercise Price Compared To Issuance Price		120.00%
Sale of Stock, Price Per Share								$ 0.29

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended		141 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012
Cash flows from operating activities:
Net loss	$ (1,702)	$ (1,802)	$ (45,780)	[1]
Less - loss for the period from discontinued operations	0	0	164	[1]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of deferred charges	77	76	1,078	[1]
Severance pay, net	1	(35)	13	[1]
Accrued interest on loans	0	0	451	[1]
Amortization of discount on short-term loans	0	0	1,864	[1]
Change in fair value of options and warrants	0	0	(795)	[1]
Expenses related to shares and options granted to service providers	8	222	21,494	[1]
Stock-based compensation related to options granted to employees	313	443	7,134	[1]
Decrease (increase) in accounts receivable and prepaid expenses	(177)	251	(558)	[1]
Increase (decrease) in trade payables	271	(11)	988	[1]
Increase in other accounts payable and accrued expenses	44	1	1,441	[1]
Erosion of restricted cash	0	0	(6)	[1]
Net cash used in continuing operating activities	(1,165)	(855)	(12,512)	[1]
Net cash used in discontinued operating activities	0	0	(23)	[1]
Total net cash used in operating activities	(1,165)	(855)	(12,535)	[1]
Cash flows from investing activities:
Purchase of property and equipment	(61)	(37)	(1,194)	[1]
Restricted cash	0	0	6	[1]
Investment in lease deposit	0	(8)	(17)	[1]
Net cash used in continuing investing activities	(61)	(45)	(1,205)	[1]
Net cash used in discontinued investing activities	0	0	(16)	[1]
Total net cash used in investing activities	(61)	(45)	(1,221)	[1]
Cash flows from financing activities:
Proceeds from issuance of Common stock, net	0	3,626	12,319	[1]
Proceeds from loans, notes and issuance of warrants, net	0	0	2,061	[1]
Proceeds from exercise of warrants and options	146	80	777	[1]
Repayment of short-term loans	0	0	(601)	[1]
Net cash provided by continuing financing activities	146	3,706	14,556	[1]
Net cash provided by discontinued financing activities	0	0	43	[1]
Total net cash provided by financing activities	146	3,706	14,599	[1]
Increase (decrease) in cash and cash equivalents	(1,080)	2,806	843	[1]
Cash and cash equivalents at the beginning of the period	1,923	93	0
Cash and cash equivalents at end of the period	843	2,899	843
Non-cash financing activities:
Conversion of convertible loan and convertible note to shares Conversion of trade payable to Common Stock $ 84	0	137
Conversion of other accounts payable to Common Stock	$ 0	$ 24

[1] Out of the which, cash flows used in discontinued operating activities of $36, cash flows used in discontinued investing activities of $16 and cash flows provided in discontinued financing activities of $57, relating to the period from inception to March 31, 2004, is unaudited.

XML

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Jun. 30, 2012	Dec. 31, 2011
Common stock, par value (in dollars per share)	$ 0.00005	$ 0.00005
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares issued	128,586,644	126,444,309
Common stock, shares outstanding	128,586,644	126,444,309

XML

RESEARCH AND LICENSE AGREEMENT (Details Textual) (USD $) In Thousands, except Share data, unless otherwise specified	1 Months Ended	12 Months Ended	111 Months Ended
	Jan. 31, 2011	Dec. 31, 2009	Dec. 24, 2009
Research License Agreement Expenses Paid			$ 400
Research License Payments Made As Per Settlement Agreement		5
Shares Granted As Per Research And License Agreement		1,120,000
Number Of Days Of Restriction To Sell Shares In Open Market		185 days
Number Of Shares Sold By Purchaser As Permitted By Settlement Agreement		167,530
Proceeds From Sale Of Shares Are Less Than240 Conditions		"Company shall pay to Ramot the difference between the proceeds that Ramot has received from sales of the shares up to such date together with the September Payment (if any) that has been transferred to Ramot up to such date, and $240."
Proceeds From Shares Sold By Purchaser As Permitted By Settlement Agreement	35
Total Value Of Shares Sold By Purchaser	235
Obligation Amount To Fund Extended Research Period			1,140
Research and Development Expenses Reversed		760
Stock Based Compensation Related To Shares Granted Under Research Licence Agreement		51
Initial Research Period [Member]
Research License Liability			240
Extended Research Period [Member]
Research License Liability			$ 380

XML

DOCUMENT AND ENTITY INFORMATION	6 Months Ended
	Jun. 30, 2012	Aug. 10, 2012
Entity Registrant Name	BRAINSTORM CELL THERAPEUTICS INC.
Entity Central Index Key	0001137883
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	bcli
Entity Common Stock, Shares Outstanding		148,405,612
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2012
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2012

XML

CONSULTING AGREEMENTS (Details Textual) (USD $) In Thousands, except Share data, unless otherwise specified	1 Months Ended			12 Months Ended				12 Months Ended			6 Months Ended	12 Months Ended	6 Months Ended		12 Months Ended
	Jul. 31, 2012	Apr. 30, 2012	Jun. 30, 2011	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2004	Jun. 30, 2012	Dec. 31, 2010 Common Stock [Member]	Dec. 31, 2011 Prof Eldad Melamed [Member]	Dec. 31, 2004 Prof Eldad Melamed [Member]	Jun. 30, 2012 Dr Daniel Offen [Member]	Dec. 31, 2004 Dr Daniel Offen [Member]	Jun. 30, 2012 Dr Daniel Offen [Member] Common Stock [Member]	Jun. 30, 2012 Dr Daniel Offen [Member] Cash [Member]	Dec. 31, 2010 Consultants [Member]
Monthly Payment Of Consulting Fees										$ 6		$ 6
Warrants Issued To Purchase Of Common Stock		33,334				1,097,215
Investment Warrants, Exercise Price	$ 0.348					$ 0.01
Deferred Compensation Arrangement with Individual, Maximum Contractual Term						seven year
Stock Issued During Period, Shares, New Issues			476,666	309,977				2,475,000	400,000						1,100,000
Consultant Charges Cancelled					487
Consultant Charges Payable							162
Consulting Expenses Monthly Payment											$ 6		$ 3	$ 3

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended		141 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012
Operating costs and expenses:
Research and development, net	$ 385	$ 586	$ 754	$ 856	$ 25,173	[1]
General and administrative	448	829	958	1,087	17,961	[1]
Total operating costs and expenses	833	1,415	1,712	1,943	43,134	[1]
Financial expenses (income), net	(4)	(191)	(15)	(14)	2,532	[1]
Other expenses (income)	0	(132)	0	(132)	(132)	[1]
Operating loss	829	1,092	1,697	1,797	45,534	[1]
Taxes on income	1	5	5	5	82	[1]
Loss from continuing operations	830	1,097	1,702	1,802	45,616	[1]
Net loss from discontinued operations	0	0	0	0	164	[2]
Net loss	$ 830	$ 1,097	$ 1,702	$ 1,802	$ 45,780	[2]
Basic and diluted net loss per share from continuing operations (in dollars per share)	$ 0.01	$ 0.01	$ 0.01	$ 0.02
Weighted average number of shares outstanding used in computing basic and diluted net loss per share (in shares)	128,078,347	121,253,983	127,334,805	115,108,731

[1] Out of which, $163, relating to the period from inception to March 31 2004, is unaudited.

[2] Out of the which, cash flows used in discontinued operating activities of $36, cash flows used in discontinued investing activities of $16 and cash flows provided in discontinued financing activities of $57, relating to the period from inception to March 31, 2004, is unaudited.

XML

CONSULTING AGREEMENTS

6 Months Ended

Jun. 30, 2012

Consulting Agreements [Abstract]

Consulting Agreements [Text Block]

NOTE 5 - CONSULTING AGREEMENTS

A. On July 8, 2004, the Company entered into two consulting agreements with Prof. Eldad Melamed and Dr. Daniel Offen (together, the "Consultants"), under which the Consultants provide the Company scientific and medical consulting services in consideration for a monthly payment of $6 each. In addition, the Company granted each of the Consultants, a fully vested warrant to purchase 1,097,215 shares of Common Stock at an exercise price of $0.01 per share. The warrants issued pursuant to the agreement were issued to the Consultants effective as of November 4, 2004. Each of the warrants is exercisable for a seven-year period beginning on November 4, 2005. As of September 2010, all the above warrants had been exercised. In June 2012 an amendment was signed with Dr. Daniel Offen, according to which the company will pay Daniel Offen a monthly payment of $6, out of which $3 in cash and $3 by grant of Company stock.

B. On December 16, 2010, the Company approved a grant of 1,100,000 shares of the Company's Common Stock to the two Consultants, for services rendered through December 31, 2010. Related compensation in the amount of $220 was recorded as research and development expense. A sum of $487 was cancelled concurrently with the issuance of the 1,100,000 shares of Common Stock of the Company.

C. On June 27, 2011, the Company approved an additional grant of 400,000 shares of the Company's Common Stock to Prof. Daniel Offen, for services rendered through December 31, 2009. Related compensation in the amount of $192 was recorded as financial expense.

D. As of June 30, 2012, the Company has a total obligation of $162 for services rendered by the Consultants under the abovementioned agreements.

XML

RESEARCH AND LICENSE AGREEMENT

6 Months Ended

Jun. 30, 2012

Research and License Agreement [Abstract]

Research and License Agreement [Text Block]

NOTE 4 - RESEARCH AND LICENSE AGREEMENT

The Company has a Research and License Agreement, as amended and restated, with Ramot. The Company obtained a waiver and release from Ramot pursuant to which Ramot agreed to an amended payment schedule regarding the Company's payment obligations under the Research and License Agreement and waived all claims against the Company resulting from the Company's previous defaults and non-payment under the Research and License Agreement. The waiver and release amended and restated the original payment schedule under the original agreement providing for payments during the initial research period and additional payments for any extended research period.

As of December 24, 2009, the Company had paid to Ramot $400 but did not make payments totaling $240 for the initial research period and payments totaling $380 for the extended research period.

On December 24, 2009, the Company and Ramot entered into a settlement agreement which amended the Research and License Agreement, as amended and restated pursuant to which, among other things, the following matters were agreed upon:

a) Ramot released the Company from its obligation to fund the extended research period in the total amount of $1,140. Therefore, the Company reversed an amount in 2009, equal to $760 from it research and development expenses that were previously expensed.

b) Past due amounts of $240 for the initial research period plus interest of $32 owed by the Company to Ramot was converted into 1,120,000 shares of common stock on December 30, 2009. Ramot was required to deposit the shares with a broker and only sell the shares in the open market after 185 days from the issuance date.

c) In the event that the total proceeds generated by sales of the shares on December 31, 2010, together with the March 31, 2010 payment, are less than $240 on or prior to December 31, 2010, then on such date the Company shall pay to Ramot the difference between the proceeds that Ramot has received from sales of the shares up to such date together with the September Payment (if any) that has been transferred to Ramot up to such date, and $240. Related compensation in the amount of $51 was recorded as research and development expenses.

In January 2011, Ramot sold an additional 167,530 shares of Common Stock of the Company, for $35, which finalized the sale of the 1,120,000 Common Stock of the Company granted to Ramot for $235. In February 2011, the Company paid the remaining $5 and finalized the balance due to Ramot according to the settlement agreement between the parties dated December 24, 2009.

XML

STOCK CAPITAL (Details Textual) (USD $)	1 Months Ended										3 Months Ended		6 Months Ended		12 Months Ended					141 Months Ended					1 Months Ended			12 Months Ended	1 Months Ended					1 Months Ended				1 Months Ended			1 Months Ended		1 Months Ended			12 Months Ended	1 Months Ended							1 Months Ended																		2 Months Ended	12 Months Ended			1 Months Ended									6 Months Ended		1 Months Ended						3 Months Ended	1 Months Ended														6 Months Ended	12 Months Ended				1 Months Ended		2 Months Ended	12 Months Ended	6 Months Ended	12 Months Ended					3 Months Ended	1 Months Ended		12 Months Ended	1 Months Ended		12 Months Ended	1 Months Ended		12 Months Ended	1 Months Ended		12 Months Ended	1 Months Ended													2 Months Ended	6 Months Ended	12 Months Ended		1 Months Ended				1 Months Ended
	Jul. 17, 2012	Jul. 31, 2012	Apr. 30, 2012	Jun. 30, 2011	Jan. 31, 2011	Apr. 30, 2010	Feb. 28, 2010	Dec. 31, 2009	Mar. 31, 2006	Jan. 31, 2006	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2004	Jun. 30, 2012		Dec. 13, 2009	Mar. 20, 2008	Mar. 06, 2006	Jun. 30, 2004 Filing Service [Member]	Jun. 30, 2011 Legal Advisor [Member]	Feb. 28, 2010 Legal Advisor [Member]	Dec. 31, 2011 Legal Advisor [Member]	Jul. 31, 2009 Finance Consultant Member [Member]	May 31, 2006 Finance Consultant Member [Member]	May 31, 2006 Business Development Advisor [Member]	Apr. 30, 2007 Filing Printing Service Providers [Member]	Apr. 12, 2007 Filing Printing Service Providers [Member]	Dec. 31, 2010 Scientific Advisory Board [Member]	Oct. 31, 2007 Scientific Advisory Board [Member]	Apr. 30, 2009 Chief Technology Advisor [Member]	Apr. 05, 2009 Chief Technology Advisor [Member]	May 31, 2010 Public Relations Advisor [Member]	Mar. 30, 2007 Convertible Promissory Note To Third Party [Member]	Mar. 05, 2007 Convertible Promissory Note To Third Party [Member]	Dec. 31, 2009 Convertible Promissory Note To Legal Advisor [Member]	Dec. 13, 2009 Convertible Promissory Note To Legal Advisor [Member]	Dec. 31, 2010 Chief Medical Advisor [Member]	Dec. 31, 2010 Chief Scientist [Member]	Jun. 30, 2011 Consultants [Member]	Dec. 31, 2010 Consultants [Member]	Jun. 30, 2011 Service Provider [Member]	May 20, 2008 Financial Advisor [Member]	Oct. 31, 2007 Financial Advisor [Member]	Jul. 31, 2009 Financial Consultant [Member]	May 31, 2006 Financial Consultant [Member]	Mar. 05, 2007 First Year [Member] Convertible Promissory Note To Third Party [Member]	Mar. 05, 2007 After First Year [Member]	Apr. 30, 2007 Restricted Stock [Member]	May 31, 2006 Restricted Stock [Member]	Jun. 30, 2011 Vestin Twelve Equal Monthly Installment [Member]	Jun. 30, 2011 Vested [Member]	Jun. 30, 2011 Director [Member]	Jan. 31, 2011 Director [Member]	Dec. 31, 2010 Director [Member]	May 31, 2010 Director [Member]	Dec. 31, 2009 Director [Member]	Aug. 31, 2009 Director [Member]	Aug. 31, 2008 Director [Member]	Aug. 31, 2007 Director [Member]	Mar. 30, 2007 Director [Member]	Mar. 31, 2007 Director [Member]	Sep. 30, 2006 Director [Member]	May 31, 2006 Director [Member]	Mar. 31, 2006 Director [Member]	Dec. 31, 2005 Director [Member]	Jun. 30, 2010 Director [Member]	Dec. 31, 2010 Director [Member]	Dec. 31, 2005 Director [Member]	Dec. 31, 2005 Chief Financial Officer [Member]	Dec. 31, 2010 Employee [Member]	Feb. 28, 2010 Employee [Member]	Jun. 30, 2006 Employee [Member]	Jul. 31, 2007 Director One [Member]	Jul. 31, 2007 Director Two [Member]	Apr. 30, 2012 Former Chief Executive Officer [Member]	Jul. 31, 2011 Former Chief Executive Officer [Member]	Jun. 30, 2009 Former Chief Executive Officer [Member]	Oct. 31, 2007 Former Chief Executive Officer [Member]	Jun. 30, 2012 Former Chief Executive Officer [Member]	Jul. 25, 2011 Former Chief Executive Officer [Member]	Apr. 30, 2012 Hadasit [Member]	Apr. 30, 2011 Hadasit [Member]	Apr. 30, 2010 Hadasit [Member]	Apr. 30, 2012 Mr Israeli [Member]	Jun. 30, 2011 Mr Israeli [Member]	Apr. 30, 2010 Mr Israeli [Member]	Jun. 30, 2012 Mr Israeli [Member]	Jan. 31, 2011 Chief Operating Officer [Member]	Apr. 30, 2010 Prof Melamed [Member]	Nov. 30, 2011 Former Director [Member]	Sep. 30, 2004 Former Director [Member]	Jul. 31, 2004 Former Director [Member]	Aug. 31, 2011 Chief Executive Officer [Member]	Nov. 30, 2008 Chief Executive Officer [Member]	Oct. 31, 2007 Chief Executive Officer [Member]	Jun. 30, 2009 Former Chief Financial Officer [Member]	Aug. 31, 2011 Scientific Board [Member]	Dec. 31, 2010 Scientific Board [Member]	Nov. 30, 2011 Board [Member]	Dec. 31, 2010 Board [Member]	Aug. 31, 2011 Mr Schor [Member]	Jun. 30, 2012 Global Share Option Plan2004 and U S Stock Option and Incentive Plan2005 [Member]	Dec. 31, 2011 Global Share Option Plan2004 and U S Stock Option and Incentive Plan2005 [Member]	Dec. 31, 2008 Global Share Option Plan2004 and U S Stock Option and Incentive Plan2005 [Member]	Dec. 31, 2004 Global Share Option Plan2004 and U S Stock Option and Incentive Plan2005 [Member]	Dec. 31, 2004 Global Share Option Plan 2004 [Member]	Apr. 30, 2006 U S Stock Option and Incentive Plan [Member]	Feb. 28, 2005 U S Stock Option and Incentive Plan [Member]	Apr. 30, 2005 U S Stock Option and Incentive Plan [Member]	Dec. 31, 2004 U S Stock Option and Incentive Plan [Member]	Jun. 30, 2012 Common Stock [Member]	Dec. 31, 2011 Common Stock [Member]	Dec. 31, 2010 Common Stock [Member]		Dec. 31, 2008 Common Stock [Member]		Jun. 30, 2011 Warrant [Member]	Jun. 30, 2004 Maximum [Member] Filing Service [Member]	Sep. 30, 2006 Maximum [Member] Director [Member]	Dec. 31, 2005 Maximum [Member] Chief Financial Officer [Member]	Jun. 30, 2006 Maximum [Member] Employee [Member]	Nov. 30, 2008 Maximum [Member] Chief Executive Officer [Member]	Dec. 31, 2010 Maximum [Member] Warrant [Member]	Jun. 30, 2004 Minimum [Member] Filing Service [Member]	Sep. 30, 2006 Minimum [Member] Director [Member]	Dec. 31, 2005 Minimum [Member] Chief Financial Officer [Member]	Jun. 30, 2006 Minimum [Member] Employee [Member]	Nov. 30, 2008 Minimum [Member] Chief Executive Officer [Member]	Dec. 31, 2010 Minimum [Member] Warrant [Member]	Mar. 31, 2011 Private Placement [Member]	Feb. 28, 2011 Private Placement [Member]	Jan. 31, 2011 Private Placement [Member]	Feb. 28, 2010 Private Placement [Member]	Jan. 31, 2010 Private Placement [Member]	Aug. 31, 2009 Private Placement [Member]	Jul. 31, 2007 Private Placement [Member]	Dec. 31, 2005 Private Placement [Member]	Aug. 31, 2005 Private Placement [Member]	Jul. 31, 2005 Private Placement [Member]	May 31, 2005 Private Placement [Member]	Mar. 31, 2005 Private Placement [Member]	Feb. 28, 2005 Private Placement [Member]	Aug. 17, 2012 Private Placement [Member]	Jun. 30, 2012 Private Placement [Member]	Dec. 31, 2004 Private Placement [Member]	Jul. 02, 2007 Private Placement [Member]	Mar. 31, 2011 Private Placement [Member] Cash [Member]	Feb. 28, 2011 Private Placement [Member] Cash [Member]	Feb. 28, 2011 Private Placement [Member] Investment Agreement [Member]	Feb. 23, 2011 Private Placement [Member] Investment Agreement [Member]	Mar. 31, 2011 Private Placement [Member] Related Party [Member]	Mar. 31, 2011 Private Placement [Member] Warrant Issued One [Member]	Feb. 28, 2011 Private Placement [Member] Warrant Issued One [Member] Investment Agreement [Member]	Mar. 31, 2011 Private Placement [Member] Warrant Issued Two [Member]	Feb. 28, 2011 Private Placement [Member] Warrant Issued Two [Member] Investment Agreement [Member]	Mar. 31, 2011 Private Placement [Member] Common Stock [Member]	Feb. 28, 2011 Private Placement [Member] Common Stock [Member]	Aug. 31, 2009 Private Placement [Member] Maximum [Member]	Aug. 31, 2005 Private Placement [Member] Maximum [Member]	Aug. 31, 2005 Private Placement [Member] Minimum [Member]
Stock Issued During Period, Shares, New Issues				476,666											309,977																			300,000												1,100,000								100,000	200,000	260,000	216,666			400,000	300,000			960,000								500,000																								250,000	15,000	20,000					300,000		500,000	400,000	923,374							100,000	400,000				2,475,000					150,000						40,000						41,666,667	833,333	10,499,999	6,000,000		9,916,667				165,000	186,875			19,818,972		8,510,000				12,815,000		1,250,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized																																																																																																												9,000,000	5,000,000	5,000,000
Shares Reserved For Issuance Under Stock Option Plan																																																																																																															9,143,462
Unit Sold Comprised Of One Share and One Warrant																																																																																																																																												1,250,000
Shares Sold Pursuant To Investment Agreement																																																																																																																																														27,500,000
Units Sold																																																																																																																																															187,500	1,250,000			312,500	1,894,808
Proceeds From Issuance Of Equity Securities																																																																																																											$ 10,000,000
Stock Based Compensation To Legal Advisor																									105,000
Price Per Unit																																																																																																																																																$ 0.8
Warrants Sold Pursuant To Investment Agreement																																																																																																																																														30,250,000
Deferred Compensation Arrangement with Individual, Maximum Contractual Term																			seven year																																											10 years	10 years		10 years	10 years				10 years	10 years		10 years			10 years	10 years		10 years	10 years			10 years	10 years					12 months																																																							3 Years
Stock Based Compensation Recorded In General and Administrative Expenses						50,000			185,000	23,000				229,000												86,000			20,000	102,000	74,000				67,000	144,000											5,000		35,000					47,000	104,000			287,000		78,000		21,000	32,000		84,000		43,000		48,000							32,000		2,000	38,000	75,000			68,000						7,000	8,000	48,000	50,000				70,000	39,000		26,000	4,000	733,000					80,000							25,800
Proceeds From Issuance Of Common Stock Gross	5,700,000																																																																																																																																								250,000		1,500,000	250,000			135,000		99,000	149,000	225,000	1,418,000			60,000
Payments of Stock Issuance Costs																																																																																																																																																							25,000
Common Stock Price Per Share																																																																																																																																																	$ 0.6	$ 0.8
Common Stock Purchase Price																																																																																																																																									$ 0.3
Common Stock, Value, Subscriptions																																																																																																																																																								5,000,000,000				3,600,000
Warrants Issued To Purchase Of Common Stock			33,334																1,097,215																																																																																																																						641,026	4,539,500	3,000,000																19,222,500			10,083,333	12,815,000	20,166,667	6,407,500
Investment Agreement Price																																																																																																																																													$ 0.12																							$ 0.1818
Investment Agreement Monthly Installment																																																																																																																																													50,000
Investment Agreement Date																																																																																				Aug. 01, 2009																																																									Aug. 01, 2009
Investment Warrants, Exercise Price		$ 0.348																	$ 0.01																																													$ 0.01																							$ 0.00005																																																		$ 0.39	$ 0.2	$ 0.5	$ 0.5				$ 1				$ 2.5		$ 0.348								$ 0.2	$ 0.5	$ 0.29	$ 0.28				$ 0.36	$ 0.29
Warrants Expire Date																																																																																																																																																Nov. 05, 2013
Investment Agreement Value																																																																																																																																										200
Deferred Compensation Arrangement with Individual, Exercise Price													$ 0.116						$ 0.01																																							$ 0.15		$ 0.15		$ 0.15	$ 0.15		$ 0.15	$ 0.15			$ 0.15		$ 0.75					$ 0.18	$ 0.32		$ 0.15	$ 0.15			$ 0.067				$ 0.00005	$ 0.00005	$ 0.00005	$ 0.00005	$ 0.00005	$ 0.00005	$ 0.00005	$ 0.2					$ 0.2		$ 0.87	$ 0.067																							$ 0.75	$ 0.75	$ 0.75	$ 0.87			$ 0.15	$ 0.15	$ 0.15	$ 0.15			$ 0.39	$ 0.2	$ 0.5											$ 0.348								$ 0.2		$ 0.29
Warrant Expiry Term																																																																																																																																									1 Year			2 year								3 years											2 Years		1 year
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross			166,666										166,666																																																							100,000	100,000						400,000			270,000															166,666								1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term																																																												10 years						10 years			10 years					10 years																											10 years
General and Administrative Expense											448,000	829,000	958,000	1,087,000						17,961,000	[1]																													20,000	102,000								112,000							43,000																																			733,000			60,000
Common Stock Purchased From Option Granted																																																										634,999		400,000		100,000	100,000		100,000	100,000								100,000		670,000	30,000		100,000	100,000			1,000,000					33,334	33,334	166,666	166,666	166,666		450,000					70,000			200,000
Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price													$ 0.00005																																																					$ 0.15								$ 0.75
Common Stock Purchased From Issuance Of Warrants																																																																1,000,000																															1,097,215
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period			483,333										(1,182,606)																																																																				483,333				1,182,606																																1,182,606	1,648,728	1,540,885		17,399																							10,083,334
Fair Value Assumptions, Risk Free Interest Rate																																																																																																																																	3.47%						2.26%
Fair Value Assumptions, Weighted Average Volatility Rate																																																																																																																																	141.00%						1.34%
Fair Value Assumptions, Expected Dividend Rate																																																																																																																											0.00%
Fair Value Assumptions, Expected Term																																																																																																																																	10 years						6 years
Compensation Expenses Filing Services																									26,000
Compensation Expenses Amortization Period																									12 months
Restricted Shares Price										$ 0.00005																																																																																																							$ 0.00005	$ 0.00005	$ 0.00005
Stock Issued During Period, Shares, Issued for Services									34,904	350,000																180,000					240,000				80,000	1,800,000		100,000					900,000	200,000	400,000		10,870	90,000		285,714	200,000																																																														60,000
Legal Fees Payable																								18,500													180,000					217,000
Stock Issued During Period Shares Issued For Services One																																80,000
Legal Fees Payable One																																	15,000
Liabilities											1,597,000		1,597,000		1,256,000					1,597,000
Convertible Loans Introduction Fee																																																																																																								300,000
Interest and Debt Expense																																																36,000
Convertible Notes Payable																						135,000																		150,000		135,000
Debt Instrument, Interest Rate, Effective Percentage																																										4.00%
Debt Instrument Principle With Interest																																								189,000
Stock Issued During Period, Shares, Conversion of Convertible Securities							402,385								445,617	1,016,109	1,120,000										402,385	445,617											1,016,109		402,385
Distribution Services Percentage																																																																																																																																									10.00%																	6.00%									4.00%
Distribution Services Shares																																																																																																																																																																		512,600
Distribution Services Value																																																																																																																																																									231,000
Stock Option Expire Date																																																																																																																Nov. 25, 2014				Mar. 28, 2015
Option Granted In Future											12,225,103		12,225,103							12,225,103
Stock Repurchased and Retired During Period, Shares																																																																																																						66,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number																																																																																						483,333
Research and Development Expense											385,000	586,000	754,000	856,000						25,173,000	[1]																									220,000																																									3,000
General and Administrative Expense One																																30,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term																																																																												3 years																															3 years
Stock Issued During Period, Value, Stock Options Exercised													137,000		243,000	77,000		3,000																																																																			20,000																																0	0	0	[2]	0	[2]
Service Management Costs																																																																																																											15,000
General Administrative Expenses																																		60,000													5,000
Sale Of Shares					167,530
Finance Consulting Fees																																																		20,000
Debt Instrument Regular Interest Rate Percentage																																																				8.00%	10.00%
Stock Based Compensation Recorded In Research Development Expenses								51,000																																			180,000	40,000	192,000																																9,000											11,000
Exercise Of Options Consideration																																																																													$ 9
Filing Printing Service Provider Liability																							20,000
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options																																																																																		$ 32,000

[1] Out of which, $163, relating to the period from inception to March 31 2004, is unaudited.

[2] Represents an amount less than $1.

XML

STOCK CAPITAL (Details) (USD $)	Jul. 02, 2007
Purchase Date August 30, 2007 [Member]
Purchase price	$ 1,250
Number of subscription shares	6,875,000
Number of warrant shares	7,562,500
Purchase Date November 15, 2007 [Member]
Purchase price	$ 750
Number of subscription shares	4,125,000
Number of warrant shares	4,537,500
Purchase Date February 15, 2008 [Member]
Purchase price	$ 750
Number of subscription shares	4,125,000
Number of warrant shares	4,537,500
Purchase Date May 15, 2008 [Member]
Purchase price	$ 750
Number of subscription shares	4,125,000
Number of warrant shares	4,537,500
Purchase Date July 30, 2008 [Member]
Purchase price	$ 750
Number of subscription shares	4,125,000
Number of warrant shares	4,537,500
Purchase Date November 15, 2008 [Member]
Purchase price	$ 750
Number of subscription shares	4,125,000
Number of warrant shares	4,537,500

XML

STOCK CAPITAL (Tables)

6 Months Ended

Jun. 30, 2012

Stockholders' Equity Note [Abstract]

Schedule Of Separate Closings Of Purchase Sale Of Shares Warrants [Table Text Block]

Separate closings of the purchase and sale of the shares and the warrants were originally scheduled to take place as follows:

Purchase date	Purchase price	Number of subscription shares		Number of warrant shares
August 30, 2007	$1,250 (includes $250 paid as a convertible loan)		6,875,000		7,562,500
November 15, 2007	$750		4,125,000		4,537,500
February 15, 2008	$750		4,125,000		4,537,500
May 15, 2008	$750		4,125,000		4,537,500
July 30, 2008	$750		4,125,000		4,537,500
November 15, 2008	$750		4,125,000		4,537,500

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the Company's option activity related to options to employees and directors, and related information is as follows:

	For the six months period ended June 30, 2012
	Amount of options			Weighted average exercise price		Aggregate intrinsic value
				$		$
Outstanding at beginning of period		4,938,821			0.168
Granted		166,666			0.00005
Exercised		(1,182,606	)		0.116
Reclassified		13,784			0.010
Outstanding at end of period		3,936,665			0.1766		407,051
Vested and expected-to-vest at end of period		3,204,999			0.1812		316,654

Schedule Of Warrants Issued To Investors Service Providers [Table Text Block]

a) Warrants to investors and service providers and investors:

Issuance date	Number of warrants issued		Exercised		Forfeited		Outstanding		Exercise Price $		Warrants exercisable		Exercisable through
November 2004		12,800,845		12,596,010		204,835		-		0.01		-		-
December 2004		1,800,000		1,800,000				-		0.00005		-		-
February 2005		1,894,808				1,894,808		-		2.5		-		-
May 2005		47,500				47,500		-		1.62		-		-
June 2005		30,000						30,000		0.75		30,000		June 2015
August 2005		70,000				70,000		-		0.15		-		-
September 2005		3,000		3,000				-		0.15		-		-
September 2005		36,000				36,000		-		0.75		-		-
September-December 2005		500,000				500,000		-		1		-		-
December 2005		477,163		170,000				307,163		0.15		307,163		December 2015
February 2006		230,000						230,000		0.65		230,000		February 2016
February 2006		40,000				40,000		-		1.5		-
February 2006		8,000				8,000		-		0.15		-
February 2006		189,000		97,696		91,304		-		0. 5		-		-
May 2006		50,000						50,000		0.0005		50,000		May 2016
May -December 2006		48,000				48,000		-		0.35		-		-
May -December 2006		48,000				48,000		-		0.75		-		-
May 2006		200,000						200,000		1		200,000		May 2016
June 2006		24,000				24,000		-		0.15		-		-
May 2006		19,355				19,355		-		0.15		-		-
October 2006		630,000		630,000				-		0.3		-		-
December 2006		200,000				200,000		-		0.45		-		-
March 2007		700,000				200,000		500,000		0.47		500,000		March 2017
March 2007		65,000				65,000		-		0.15		-		-
February 2007		50,000				50,000		-		0.45		-		-
March 2007		275,000				275,000		-		0.45		-		-
April 2007		33,300				33,300		-		0.45		-		-
May 2007		250,000				250,000		-		0.45		-		-
July 2007		500,000						500,000		0.39		500,000		July 2017
September 2007		500,000						500,000		0.15		500,000		August 2017
August 2007		7,562,500						7,562,500		0.2		7,562,500		November 2013
July 2007		130,000				130,000		-		0.45		-		-
October 2007		200,000						200,000		0.15		200,000		October 2017
November 2007		2,520,833						2,520,833		0.20		2,520,833		November 2013
November 2007		2,016,667						2,016,667		0.29		2,016,667		November 2013
April 2008		4,537,500						4,537,500		0.29		4,537,500		November 2013
August 2008		3,529,166						3,529,166		0.29		3,529,166		November 2013
August 2008		1,008,334						1,008,334		0.29		1,008,333		November 2013
November 2008		100,000						100,000		0.15		100,000		September 2018
April 2009		200,000						200,000		0.1		200,000		April 2019
October 2009		200,000		100,000				100,000		0.067		66,667		October 2019
October 2009		4,537,500						4,537,500		0.29		4,537,500		November 2013
January 2010		1,250,000				1,250,000		-		0.5		-		-
February 2010		125,000		125,000				-		0.01		-		-
February 2010		3,000,000				3,000,000		-		0.5		-		-
January 2011		4,537,500						4,537,500		0.29		4,537,500		November 2013
February 2011		641,026				641,026		-		0.39		-		-
February 2011		6,407,500		946,834		5,460,666		-		0.28		-		-
February 2011		12,815,000						12,815,000		0.5		12,815,000		February 2013
April 2010		33,334						33,334		0.00005		33,334		April 2020
April 2011		33,334						33,334		0.00005		33,334		April 2021
February 2010		1,500,000						1,500,000		0.00005		500,000		February 2020
April 2012		33,334						33,334		0.00005		33,334		April 2022
		78,637,499		16,468,540		14,586,794		47,582,165				46,548,831

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The total stock-based compensation expense, related to shares, options and warrants granted to employee’s directors and service providers, was comprised, at each period, as follows:

									Period from
									September 22,
									2000 (inception
	Six months				Three months				date) through
	ended June 30,				ended June 30,				June 30,
	2012		2011		2012		2011		2012
	Unaudited				Unaudited				Unaudited
Research and development		25		19		12		10		17,581
General and administrative		296		454		128		456		10,409
Financial expenses, net		-		192		-		192		248
Total stock-based compensation expense		321		665		140		658		28,238

XML

STOCK CAPITAL

6 Months Ended

Jun. 30, 2012

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

NOTE 6 - STOCK CAPITAL

A. The rights of Common Stock are as follows:

Holders of Common Stock have the right to receive notice to participate and vote in general meetings of the Company, the right to a share in the excess of assets upon liquidation of the Company and the right to receive dividends, if declared.

The Common Stock is registered and publicly traded on the Over-the-Counter Bulletin Board service of the National Association of Securities Dealers, Inc. under the symbol BCLI.

B. Issuance of shares warrants and options:

1. Private placements:

a) On June 24, 2004, the Company issued to investors 8,510,000 shares of Common Stock for total proceeds of $60 (net of $25 issuance expenses).

b) On February 23, 2005, the Company completed a private placement for sale of 1,894,808 units for total proceeds of $1,418. Each unit consists of one share of Common Stock and a three-year warrant to purchase one share of Common Stock at $2.50 per share. This private placement was consummated in three tranches which closed in October 2004, November 2004 and February 2005.

c) On May 12, 2005, the Company issued to an investor 186,875 shares of Common Stock at a price of $0.8 per share for total proceeds of $149.

d) On July 27, 2005, the Company issued to investors 165,000 shares of Common Stock at a price of $0.6 per share for total proceeds of $99.

e) On August 11, 2005, the Company signed a private placement agreement with investors for the sale of up to 1,250,000 units at a price of $0.8 per unit. Each unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock at $1.00 per share. The warrants are exercisable for a period of three years from issuance. On March 31, 2005, the Company sold 312,500 units for total net proceeds of $225. On December 7, 2005, the Company sold 187,500 units for total net proceeds of $135.

f) On July 2, 2007, the Company entered into an investment agreement, pursuant to which the Company agreed to sell up to 27,500,000 shares of Common Stock, for an aggregate subscription price of up to $5 million and warrants to purchase up to 30,250,000 shares of Common Stock. Separate closings of the purchase and sale of the shares and the warrants were originally scheduled to take place as follows:

Purchase date	Purchase price	Number of subscription shares		Number of warrant shares
August 30, 2007	$1,250 (includes $250 paid as a convertible loan)		6,875,000		7,562,500
November 15, 2007	$750		4,125,000		4,537,500
February 15, 2008	$750		4,125,000		4,537,500
May 15, 2008	$750		4,125,000		4,537,500
July 30, 2008	$750		4,125,000		4,537,500
November 15, 2008	$750		4,125,000		4,537,500

On August 18, 2009, the Company entered into an amendment to the investment agreement with the investor providing for the following:

(a) The investor shall invest the remaining amount of the original investment agreement at price per share of $0.12 in monthly installments of not less than $50 starting August 1, 2009. The investor may accelerate such payments at its discretion.

(b) The exercise price of the last 10,083,334 warrants decreased from an exercise price of $0.36 per share to $0.29 per share.

(c) All warrants expire on November 5, 2013 instead of November 5, 2011.

(d) The price per share of the investment agreement decreased from $0.1818 to $0.12, therefore the Company adjusted the number of Shares of Common Stock issuable pursuant the investment agreement retroactively and issued to the investor on October 28, 2009 an additional 9,916,667 shares of Common Stock for past investment.

(e) The investor has the right to cease payments in the event that the price per share as of the closing on five consecutive trading days shall decrease to $0.05.

On January 18, 2011, the Company and an investor signed an agreement to balance amounts due to the investor, totaling $20, against the remaining balance of the investment. The Company issued to the investor 10,499,999 shares of Common Stock and a warrant to purchase 4,539,500 shares of the Company's Common Stock at an exercise price of $0.20 per share

As of March 31, 2011, the Company issued to the investor and its designees an aggregate of 41,666,667 shares of common stock and a warrant to purchase 10,083,333 shares of the Company's common stock at an exercise price of $0.20 per share and a warrant to purchase 20,166,667 shares of common stock at an exercise price of $0.29 per share. The warrants may be exercised at any time and expire on November 5, 2013.

In addition, the Company agreed to issue an aggregate of 1,250,000 shares of Common Stock to a related party as an introduction fee for the investment. The shares shall be issued pro rata to the funds received from the investor.

As of December 31, 2010, the introduction fee was paid in full.

g) In January 2010, the Company issued 1,250,000 units to a private investor for total proceeds of $250. Each unit consists of one share of Common Stock and a two-year warrant to purchase one share of Common Stock at $0.50 per share.

h) In February 2010, the Company issued 6,000,000 shares of Common Stock to 3 investors (2,000,000 to each investor) and warrants to purchase an aggregate of 3,000,000 shares of Common Stock (1,000,000 to each investor) with an exercise price of $0.5 for aggregate proceeds of $1,500 ($500 each).

i) On February 7, 2011, the Company issued 833,333 shares of Common Stock, at a price of $0.3 per share, and a warrant to purchase 641,026 shares of the Company's Common Stock at an exercise price of $0.39 per share for one year for total proceeds of $250.

j) On February 23, 2011, the Company entered into an investment agreement, pursuant to which the Company agreed to sell up to 12,815,000 shares of Common Stock, for an aggregate subscription price of up to $3.6 million and warrants to purchase up to 19,222,500 shares of Common Stock as follows: warrant to purchase 12,815,000 shares of Common Stock at $0.5 for two years, and warrants to purchase 6,407,500 shares of Common Stock at $0.28 for one year, out of which 946,834 were exercised, and 5,460,666 were cancelled.

In addition, the Company agreed to pay 10% of the funds received for the distribution services received, out of this amount, 4% was be paid in stock and the remaining 6% in cash. Accordingly, in March 2011, the Company issued 512,600 shares of Common Stock and paid $231.

2. Share-based compensation to employees and to directors:

a) Options to employees and directors:

On November 25, 2004, the Company's stockholders approved the 2004 Global Stock Option Plan and the Israeli Appendix thereto (which applies solely to participants who are residents of Israel) and on March 28, 2005, the Company's stockholders approved the 2005 U.S. Stock Option and Incentive Plan, and the reservation of 9,143,462 shares of Common Stock for issuance in the aggregate under these stock option plans.

Each option granted under the plans is exercisable until the earlier of ten years from the date of grant of the option or the expiration dates of the respective option plans. The 2004 and 2005 options plans will expire on November 25, 2014 and March 28, 2015, respectively. The exercise price of the options granted under the plans may not be less than the nominal value of the shares into which such options are exercised. The options vest primarily over three years. Any options that are canceled or forfeited before expiration become available for future grants.

On June 5, 2008, the Company's stockholders approved an amendment and restatement of the Company’s 2004 Global Share Option Plan and 2005 U.S. Stock Option and Incentive Plan to increase the number of shares of common stock available for issuance under these stock option plans in the aggregate by 5,000,000 shares.

In June 2011, the Company's stockholders approved an increase in the number of shares of common stock available for issuance under these stock option plans in the aggregate by 5,000,000 shares.

In June 2012, the Company's stockholders approved an increase in the number of shares of common stock available for issuance under these stock option plans in the aggregate by 9,000,000 shares.

As of June 30, 2012, 12,225,103 options are available for future grants.

On May 27, 2005, the Company granted one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.75 per share. The option is fully vested and expires after 10 years.

On February 6, 2006, the Company entered into an amendment to the Company's option agreement with the Company's former Chief Financial Officer. The amendment changed the exercise price of the 400,000 options granted to him on February 13, 2005 from $0.75 to $0.15 per share.

On May 2, 2006, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and expires after 10 years. The compensation related to the option, in the amount of $48, was recorded as general and administrative expense.

On June 22, 2006, the Company entered into an amendment to the Company's option agreement with two of its employees. The amendment changed the exercise price of 270,000 options granted to them from $0.75 to $0.15 per share. The excess of the fair value resulting from the modification, in the amount of $2, was recorded as general and administration expense over the remaining vesting period of the options.

On September 17, 2006, the Company entered into an amendment to the Company's option agreement with one of its directors. The amendment changed the exercise price of 100,000 options granted to the director from $0.75 to $0.15 per share.

On March 21, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $43, was recorded as general and administrative expense.

On July 1, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $38, was recorded as general and administrative expense. On October 22, 2007, the Company and the director agreed to cancel and relinquish all the options which were granted on July 1, 2007.

On July 16, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $75, was recorded as general and administrative expense.

On August 27, 2007, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $84, was recorded as general and administrative expense.

On October 23, 2007, the Company granted to its Chief Executive Officer an option to purchase 1,000,000 shares of Common Stock at an exercise price of $0.87 per share. The option is fully vested and expires after 10 years. The total compensation related to the option is $733, which is amortized over the vesting period as general and administrative expense.

On November 5, 2008, the Company entered into an amendment to the Company's option agreement with the Company's Chief Executive Officer. The amendment changed the exercise price of the 1,000,000 options from $0.87 to $0.15 per share. The compensation related the modification of the purchase price in the amount of $4 was recorded as general and administrative expense.

On June 29, 2009, the Company granted to its former Chief Executive Officer and director an option to purchase 1,000,000 shares of Common Stock at an exercise price of $0.067 per share. The option vests with respect to 1/3 of the shares subject to the option on each anniversary of the date of grant and expires after 10 years. The total compensation related to the option is $68, which is amortized over the vesting period as general and administrative expense. In February 2011, the former CEO resigned. On July 25, 2011, the Company signed a settlement agreement with the former CEO under which 483,333 shares out of the above grant became fully vested and exercisable through April 30, 2012. An additional $30 was written as compensation in general and administrative expense. In April 2012, the former CEO exercised the option to 483,333 shares of Common Stock for an exercise price of $32.

On June 29, 2009, the Company granted to its former Chief Financial Officer an option to purchase 200,000 shares of Common Stock at an exercise price of $0.067 per share. The option vested with respect to 1/3 of the shares subject to the option. In connection with the former Chief Financial Officer’s resignation, 2/3 of the above shares were cancelled and the remaining 66,667 were valid through April 7, 2011.

On August 31, 2009, the Company granted to two of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. Each option vests with respect to 1/3 of the shares subject to the option on each anniversary of the date of grant and expires after 10 years. The total compensation related to the option is $32, which is amortized over the vesting period as general and administrative expense.

On December 13, 2009, the Company granted to one of its directors an option to purchase 100,000 shares of Common Stock at an exercise price of $0.15 per share. The option is fully vested and is exercisable for a period of 10 years. The compensation related to the option, in the amount of $21, was recorded as general and administrative expense.

On February 10, 2010, the Company granted to an employee an option to purchase 30,000 shares of Common Stock at an exercise price of $0.32 per share. The option vests with respect to 1/3 of the shares subject to the option on each anniversary of the date of grant and expires after 10 years. The total compensation related to the option is $9, which is amortized over the vesting period as research and development expense.

On April 13, 2010, the Company, Abraham Israeli and Hadasit Medical Research Services and Development Ltd. (“Hadasit”) entered into an Agreement (the “Agreement”) pursuant to which Mr. Israeli agreed, during the term of the Agreement, to serve as (i) the Company’s Clinical Trials Advisor and (ii) a member of the Company’s Board of Directors.  In consideration of the services to be provided by Mr. Israeli to the Company under the Agreement, the Company agreed to grant options annually during the term of the Agreement for the purchase of its Common Stock, as follows:

· An option for the purchase of 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share to Mr. Israeli; and

· An option for the purchase of 33,334 shares of Common Stock at an exercise price equal to $0.00005 per share to Hadasit,

Such options will vest and become exercisable in twelve (12) consecutive equal monthly amounts.

In April 2010, the Company granted to Mr. Israeli an option to purchase 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share. The total compensation related to the option was $50, which is amortized over the vesting period as general and administrative expense.

On December 16, 2010, the Company granted to two of its directors an option to purchase 400,000 shares of Common Stock at an exercise price of $0.15 per share. The options are fully vested and are exercisable for a period of 10 years. The compensation related to the option, in the amount of $78, was recorded as general and administrative expense.

On December 16, 2010, the Company approved the grant to two Board members an option to purchase 400,000 shares of Common Stock of the Company (200,000 shares each). The compensation related to the option, in the amount of $80, was recorded as general and administrative expense.

On December 16, 2010, the Company approved the grant to its three Scientific Board members 300,000 shares of Common Stock of the Company. The compensation related to the option, in the amount of $60, was recorded as research and development expense

On December 16, 2010, the Company granted to its employees options to purchase 670,000 shares of Common Stock at an exercise price of $0.18 per share. The options are vested over three years and are exercisable for a period of 10 years. The compensation related to the option, in the amount of $32, was recorded as general and administrative expense.

On January 30, 2011 the Company signed an agreement with a new COO and acting CEO. According to the employment agreement, the new COO received 450,000 options to purchase Common Stock of the Company at $0.20.

On June 27, 2011, the Company granted to Mr. Israeli an option to purchase 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share. The total compensation related to the option was $48, which is amortized over the vesting period as general and administrative expense.

On June 27, 2011, the Company granted to four of its directors options to purchase an aggregate of 634,999 shares of Common Stock of the Company at $0.15. The total compensation related to the option was $287, which is amortized over the vesting period as general and administrative expense.

On August 10, 2011, the Company granted to its CEO, an option to purchase 70,000 shares of Common Stock of the Company at $0.20. The total compensation related to the option was $26, which was amortized as general and administrative expense.

In April 2012, the Company granted to Mr. Israeli an option to purchase 166,666 shares of Common Stock at an exercise price equal to $0.00005 per share. The compensation related to the option of $8, was amortized over the vesting period as general and administrative expense.

In the six months ended June 30, 2012, 1,182,606 options were exercised by the former CEO of the Company for $20.

A summary of the Company's option activity related to options to employees and directors, and related information is as follows:

	For the six months period ended June 30, 2012
	Amount of options			Weighted average exercise price		Aggregate intrinsic value
				$		$
Outstanding at beginning of period		4,938,821			0.168
Granted		166,666			0.00005
Exercised		(1,182,606	)		0.116
Reclassified		13,784			0.010
Outstanding at end of period		3,936,665			0.1766		407,051
Vested and expected-to-vest at end of period		3,204,999			0.1812		316,654

b. Restricted shares to directors:

On May 2, 2006, the Company issued to two of its directors 200,000 restricted shares of common stock (100,000 each). The restrictions on the shares have fully lapsed. The compensation related to the stocks issued amounted to $104, which was amortized over the vesting period as general and administrative expenses.

On April 20, 2007, based on a board resolution dated March 21, 2007, the Company issued to a director 100,000 restricted shares of Common Stock. The restrictions on the shares have fully lapsed. The compensation related to the shares issued amounted to $47, which was amortized over the vesting period as general and administrative expenses.

In addition, on April 20, 2007, based on a board resolution dated March 21, 2007, the Company issued to another director 100,000 restricted shares of Common Stock. The restricted shares are not subject to any right to repurchase, and the compensation related to the shares issued amounted to $47 was recorded as prepaid general and administrative expenses in the three months ended March 31, 2007.

On August 27, 2008, the Company issued to one of its directors 960,000 shares of Common Stock upon a cashless exercise by a shareholder of a warrant to purchase 1,000,000 shares of Common Stock at an exercise price of $.01 per share that was acquired by the shareholder from Ramot. The shares were allocated to the director by the shareholder.

In May 2010, based on a board resolution dated June 29, 2009, the Company issued to three of its directors 300,000 restricted shares of Common Stock. The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date.

In May and in June 2010, based on a board resolution dated June 29, 2009, the Company issued to three of its Scientific Advisory Board members and two of its Advisory Board members 500,000 restricted shares of common stock. The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date.

On December 16, 2010, the Company granted to two of its directors 400,000 (total) shares of Common Stock. Related compensation in the amount of $80 was recorded as general and administrative costs in 2010. These shares were actually granted in June 2011, and an additional related compensation in the amount of $112 was recorded as general and administrative expense.

On June 27, 2011, the Company granted to two of its directors 476,666 (total) shares of Common Stock, out of which 216,666 shares are fully vested and 260,000 shares will vest in 12 equal monthly installments through June 2012. Related compensation in the amount of $229 will be recorded as general and administrative expense.

On August 22, 2011, the Company entered into an agreement with Chen Schor (the “Executive Director Agreement”) pursuant to which the Company granted to Mr. Schor 923,374 shares of restricted Common Stock of the Company. The shares will vest over a three-year period. If the Company raises $10,000,000 of proceeds through the issuance of equity securities in a private or public offering after the Grant Date, or enters into a deal with a strategic partner that brings in at least $10,000,000 of gross proceeds, then 1/3 of the shares will vest upon such event, 1/3 will vest on the anniversary of the Grant Date and the remaining 1/3 will vest on the second anniversary of the Grant Date. If such capital is not raised as mentioned above, then the shares will vest over 3 years – 1/3 upon each anniversary of the Grant Date. In addition, the Company will pay $15,000 per quarter to Mr. Schor for his services as an Executive Board Member.

In August 2011, the Company issued to three of its Scientific Advisory Board members and three of its Advisory Board members a total of 300,000 restricted shares of Common Stock. The restrictions of the shares shall lapse over the service period in 12 equal monthly portions.

In November 2011, the Company issued to four of its Advisory Board members a total of 500,000 restricted shares of Common Stock. The restrictions of the shares shall lapse over the service period, in equal 12 monthly portions.

In addition, in November 2011, the Company issued to a former director 250,000 shares of Common Stock. Related compensation in the amount of $70 was recorded as general and administrative expense

3. Shares and warrants to investors and service providers:

The Company accounts for shares and warrants issued to non-employees using the guidance of ASC 718-10 (formerly "SFAS" 123(R)), "Accounting for Stock-Based Compensation" and ASC 505-50-30 (formerly "EITF" 96-18), "Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling, Goods or Services," whereby the fair value of such option and warrant grants is determined using a Black-Scholes options pricing model at the earlier of the date at which the non-employee's performance is completed or a performance commitment is reached.

In April 2010, the Company granted Hadasit an option to purchase 33,334 shares of Common Stock at an exercise price equal to $0.00005 per share. The total compensation related to the option is $7, which is amortized over the vesting period as general and administrative expense.

On December 31, 2011, the Company issued to Hadasit warrants to purchase up to 1,500,000 restricted shares of the Company's Common Stock at an exercise price of $0.001 per share, exercisable for a period of 5 years. The warrants shall vest over the course of the trials as follows: 500,000 upon enrollment of 1/3 of the patients; an additional 500,000 upon enrollment of all the patients and the final 500,000 upon completion of the study.

In April 2011, the Company granted Hadasit an option to purchase 33,334 shares of Common Stock at an exercise price equal to $0.00005 per share. The total compensation related to the option is $11, which is amortized over the vesting period as research and development expense.

In April 2012, the Company granted Hadasit an option to purchase 33,334 shares of Common Stock at an exercise price equal to $0.00005 per share. The compensation related to the option of $3, was amortized over the vesting period as research and development expense.

a) Warrants to investors and service providers and investors:

Issuance date	Number of warrants issued		Exercised		Forfeited		Outstanding		Exercise Price $		Warrants exercisable		Exercisable through
November 2004		12,800,845		12,596,010		204,835		-		0.01		-		-
December 2004		1,800,000		1,800,000				-		0.00005		-		-
February 2005		1,894,808				1,894,808		-		2.5		-		-
May 2005		47,500				47,500		-		1.62		-		-
June 2005		30,000						30,000		0.75		30,000		June 2015
August 2005		70,000				70,000		-		0.15		-		-
September 2005		3,000		3,000				-		0.15		-		-
September 2005		36,000				36,000		-		0.75		-		-
September-December 2005		500,000				500,000		-		1		-		-
December 2005		477,163		170,000				307,163		0.15		307,163		December 2015
February 2006		230,000						230,000		0.65		230,000		February 2016
February 2006		40,000				40,000		-		1.5		-
February 2006		8,000				8,000		-		0.15		-
February 2006		189,000		97,696		91,304		-		0. 5		-		-
May 2006		50,000						50,000		0.0005		50,000		May 2016
May -December 2006		48,000				48,000		-		0.35		-		-
May -December 2006		48,000				48,000		-		0.75		-		-
May 2006		200,000						200,000		1		200,000		May 2016
June 2006		24,000				24,000		-		0.15		-		-
May 2006		19,355				19,355		-		0.15		-		-
October 2006		630,000		630,000				-		0.3		-		-
December 2006		200,000				200,000		-		0.45		-		-
March 2007		700,000				200,000		500,000		0.47		500,000		March 2017
March 2007		65,000				65,000		-		0.15		-		-
February 2007		50,000				50,000		-		0.45		-		-
March 2007		275,000				275,000		-		0.45		-		-
April 2007		33,300				33,300		-		0.45		-		-
May 2007		250,000				250,000		-		0.45		-		-
July 2007		500,000						500,000		0.39		500,000		July 2017
September 2007		500,000						500,000		0.15		500,000		August 2017
August 2007		7,562,500						7,562,500		0.2		7,562,500		November 2013
July 2007		130,000				130,000		-		0.45		-		-
October 2007		200,000						200,000		0.15		200,000		October 2017
November 2007		2,520,833						2,520,833		0.20		2,520,833		November 2013
November 2007		2,016,667						2,016,667		0.29		2,016,667		November 2013
April 2008		4,537,500						4,537,500		0.29		4,537,500		November 2013
August 2008		3,529,166						3,529,166		0.29		3,529,166		November 2013
August 2008		1,008,334						1,008,334		0.29		1,008,333		November 2013
November 2008		100,000						100,000		0.15		100,000		September 2018
April 2009		200,000						200,000		0.1		200,000		April 2019
October 2009		200,000		100,000				100,000		0.067		66,667		October 2019
October 2009		4,537,500						4,537,500		0.29		4,537,500		November 2013
January 2010		1,250,000				1,250,000		-		0.5		-		-
February 2010		125,000		125,000				-		0.01		-		-
February 2010		3,000,000				3,000,000		-		0.5		-		-
January 2011		4,537,500						4,537,500		0.29		4,537,500		November 2013
February 2011		641,026				641,026		-		0.39		-		-
February 2011		6,407,500		946,834		5,460,666		-		0.28		-		-
February 2011		12,815,000						12,815,000		0.5		12,815,000		February 2013
April 2010		33,334						33,334		0.00005		33,334		April 2020
April 2011		33,334						33,334		0.00005		33,334		April 2021
February 2010		1,500,000						1,500,000		0.00005		500,000		February 2020
April 2012		33,334						33,334		0.00005		33,334		April 2022
		78,637,499		16,468,540		14,586,794		47,582,165				46,548,831

The fair value for the warrants to service providers was estimated on the date of grant using a Black-Scholes option pricing model, with the following weighted-average assumptions for the year ended December 31, 2010; weighted average volatility of 140%, risk free interest rates of 2.39%-3.14% dividend yields of 0% and a weighted average life of the options of 5-5.5 years. All grants were through December 31, 2010. There were no grants that were calculated using Black-Scholes option pricing model in 2011 and in the six months ended June 30, 2012.

b) Shares:

On June 1 and June 4, 2004, the Company issued 40,000 and 150,000 shares of Common Stock for 12 months of filing services and legal and due-diligence services, respectively, with respect to a private placement. Compensation expense related to filing services, totaling $26, was amortized over a 12-month period. Compensation related to legal services, totaling $105 was recorded as equity issuance cost and had no effect on the statement of operations.

On July 1 and September 22, 2004, the Company issued 20,000 and 15,000 shares to a former director for financial services for the first and second quarters of 2004, respectively. Related compensation in the amount of $39 was recorded as general and administrative expense.

On February 10, 2005, the Company signed an agreement with one of its service providers under which the Company issued the service provider 100,000 restricted shares at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan of the Company. All restrictions on these shares have lapsed.

In March and April 2005, the Company signed an agreement with four members of its Scientific Advisory Board under which the Company issued to the members of the Scientific Advisory Board 400,000 restricted shares at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan (100,000 each). All restrictions on these shares have lapsed.

In July 2005, the Company issued to its legal advisors 50,000 shares for legal services for 12 months. The compensation related to the shares in the amount of $37.5 was recorded as general and administrative expense.

In January 2006, the Company issued to two service providers 350,000 restricted shares at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan of the Company. All restrictions on these shares have lapsed. Related compensation in the amount of $23 was recorded as general and administrative expense.

On March 6, 2006, the Company issued to its legal advisor 34,904 shares of Common Stock. The shares are in lieu of $18.5 payable to the legal advisor. Related compensation in the amount of $18.5 was recorded as general and administrative expense.

On April 13, 2006, the Company issued to service providers 60,000 shares of Common Stock at a purchase price of $0.00005 par value under the U.S. Stock Option and Incentive Plan of the Company. Related compensation in the amount of $25.8 was recorded as general and administrative expense.

On May 9, 2006, the Company issued to its legal advisor 65,374 shares of Common Stock in lieu of payment for legal services. Related compensation in the amount of $33 was recorded as general and administrative expense.

On June 7, 2006, the Company issued to a service provider 50,000 shares of Common Stock for filing services for 12 months. Related compensation in the amount of $24.5 was recorded as general and administrative expense.

On May 5, 2006, the Company issued 200,000 shares of Common Stock to a finance consultant for his services. Related compensation in the amount of $102 was recorded as general and administrative expense.

On August 14, 2006, the Company issued 200,000 shares of Common Stock to a service provider. Related compensation in the amount of $68 was recorded as general and administrative expense.

On August 17, 2006, the Company issued 100,000 shares of Common Stock to a service provider. Related compensation in the amount of $35 was recorded as general and administrative expense.

On September 17, 2006, the Company issued to its legal advisor 231,851 shares of Common Stock in lieu of $63 payable to the legal advisor. Related compensation in the amount of $63 was recorded as general and administrative expense.

On April 1 and September 30, 2006, the Company issued to its business development advisor, based on an agreement, 240,000 shares of Common Stock. Related compensation in the amount of $74 was recorded as general and administrative expense.

On January 3, 2007, the Company issued to its legal advisor 176,327 shares of Common Stock in lieu of $45 payable to the legal advisor. Related compensation in the amount of $49 was recorded as general and administrative expense.

On April 12, 2007, the Company issued to its filing and printing service providers 80,000 shares of Common Stock in lieu of $15 payable to the service provider. Related compensation in the amount of $30 was recorded as general and administrative expense. In addition, the Company was obligated to issue the filing and printing service providers additional shares, in the event that the total value of the shares previously issued (as quoted on the Over-the-Counter Bulletin Board or such other exchange where the Common Stock is quoted or listed) was less than $0.20 on March 20, 2008. As a result, the Company recorded a liability in the amount of $20.

On April 12, 2007, the Company issued to its legal advisor 108,511 shares of Common Stock in lieu of $29 payable to the legal advisor. Related compensation in the amount of $40 was recorded as general and administrative expense.

On May 18, 2007, the Company issued to its legal advisor 99,257 shares of Common Stock in lieu of $33 payable to the legal advisor. Related compensation in the amount of $33 was recorded as general and administrative expense.

On October 29, 2007, the Company issued to a scientific advisory board member 80,000 shares of the Company’s Common Stock for scientific services. Compensation of $67 was recorded as research and development expense.

On May 20, 2008, the Company issued to its financial advisor 90,000 shares of the Company's Common Stock. The shares were for $35 payable to the financial advisor for introduction fee of past convertible loans. Related compensation in the amount of $36 was recorded as financial expenses.

On April 5, 2009, the Company issued to its Chief Technology Advisor 1,800,000 shares of Common Stock. The shares were for $180 payable to the advisor. Related compensation in the amount of $144 was recorded as research and development expense.

On June 24, 2009, the Company issued to its public relations advisor 250,000 shares of Common Stock. The shares were for $25 payable to the advisor. Related compensation in the amount of $18 was recorded as general and administrative expense.

On July 8, 2009, the Company issued to its financial consultant 285,714 shares of the Company's Common Stock. The shares were for $20 payable to the financial consultant for valuation of options and warrants. Related compensation in the amount of $20 was recorded as general and administrative expense.

On July 15, 2009, the Company issued to a service provider 357,142 shares of the Company's Common Stock. The shares were for $25 payable to the service provider for filing services. Related compensation in the amount of $21 was recorded as general and administrative expense.

On August 10, 2009, the Company issued to a service provider 71,428 shares of the Company's Common Stock. The shares were for $5 payable to the service provider for IT services. Related compensation in the amount of $4 was recorded as general and administrative expense.

On January 5, 2010, the Company issued to its public relations advisor 50,000 shares of the Company's Common Stock for six months service. The issuance of the shares is part of the agreement with the public relations advisor that entitled them to a monthly grant of 8,333 shares of the Company's Common Stock. Related compensation in the amount of $12 was recorded as general and administrative expense.

On January 6, 2010, the Company issued to a service provider 60,000 shares of the Company's Common Stock. The shares were for $15 payable to the service provider for insurance and risk management consulting and agency services for three years. Related compensation in the amount of $16 was recorded as general and administrative expense.

On March 5, 2007, the Company issued a $150 Convertible Promissory Note to a third party. Interest on the note accrued at the rate of 8% per annum for the first year and 10% per annum after the first year. On January 27, 2010, the third party converted the entire accrued principle and interest outstanding under the note, amounting to $189, into 1,016,109 shares of Common Stock.

On December 13, 2009, the Company issued a $135 Convertible Promissory Note to it legal advisor for $217 in legal fees accrued through October 31, 2009. Interest on the note accrued at the rate of 4%. On February 19, 2010, the Company’s legal advisor converted the entire accrued principal and interest of outstanding under the note into 402,385 shares of Common Stock.

On April 6, 2010, Prof. Melamed fully exercised his warrant to purchase 1,097,215 shares of the Company’s Common Stock; the warrant was issued to him pursuant to the agreement with the Consultants effective as of November 4, 2004.

In May 2010, based on a board resolution dated June 29, 2009 the Company issued to one of its public relations advisors 100,000 restricted shares of Common Stock. The restrictions of the shares shall lapse in three annual and equal portions commencing with the grant date.

On December 16, 2010, the Company issued to a service provider 83,333 shares of the Company's Common Stock. The shares were for public relations services. Related compensation in the amount of $40 was recorded as general and administrative expense.

On December 16, 2010, the Company granted to its Chief Medical Advisor 900,000 shares of the Company's Common Stock for services rendered through December 31 2010. Related compensation in the amount of $180 was recorded as research and development expense (see Note 5B).

On December 16, 2010, the Company granted to its Chief Scientist 200,000 shares of the Company's Common Stock for services rendered through December 31, 2010. Related compensation in the amount of $40 was recorded as research and development expense (see Note 5B).

On February 16, 2011, one of the Company's consultants exercised 100,000 warrants to Common Stock for $33.

On February 18, 2011, the Company's legal advisor converted the entire accrued principal and interest of the Convertible Promissory Note granted on September 15, 2010, totaling $137, into 445,617 shares of Common Stock.

On June 27, 2011, the Company granted to its legal advisor 180,000 shares of Common Stock for 2011 legal services. Half of the shares of Common Stock are fully vested and half vest in six equal monthly installments through December 2011. Related compensation in the amount of $86 is recorded as general and administrative expense.

On June 27, 2011, the Company granted to its consultant 400,000 shares of the Company's Common Stock, for services rendered through December 31, 2009. Related compensation in the amount of $192 is recorded as research and development expense. (See note 4 C).

On June 27, 2011, the Company granted to a service provider 10,870 shares of the Company's Common Stock. Related compensation in the amount of $5 is recorded as general and administrative expense.

The total stock-based compensation expense, related to shares, options and warrants granted to employee’s directors and service providers, was comprised, at each period, as follows:

									Period from
									September 22,
									2000 (inception
	Six months				Three months				date) through
	ended June 30,				ended June 30,				June 30,
	2012		2011		2012		2011		2012
	Unaudited				Unaudited				Unaudited
Research and development		25		19		12		10		17,581
General and administrative		296		454		128		456		10,409
Financial expenses, net		-		192		-		192		248
Total stock-based compensation expense		321		665		140		658		28,238

XML

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2012

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 7       - SUBSEQUENT EVENTS

On July 17, 2012, the Company raised a $5.7 million through a public offering (“Public Offering”) of its common stock. The Company issued a total of 19,818,972 common stock of $0.00005 par value, ($0.29 per share) and warrants to purchase 0.75 shares of Common Stock for every share purchased in the Public Offering, at an exercise price of $0.29 per share. The Warrants are exercisable until the 30 month anniversary of the date of issuance. After deducting closing costs and fees, the Company received net proceeds of approximately $4.9 million.

The Company also paid to the Placement Agency, Maxim Group LLC (the “Placement Agent”) a cash fee equal to 6% of the gross proceeds of the Public Offering and a corporate finance fee of 1% of the gross proceeds of the Public Offering, as well as fees and expenses of the Placement Agent of $100,000.  In addition, the Company issued to the Placement Agent a two year warrant to purchase up to 594,569 shares of Common Stock (equal to 3% of the number of shares sold in the Public Offering), with an exercise price equal to $0.348 (120% of the Public offering price). The Warrants are exercisable until the 30 month anniversary of the date of issuance.

XML

GENERAL (Details Textual) (USD $) In Thousands, except Share data, unless otherwise specified	1 Months Ended		3 Months Ended		6 Months Ended			9 Months Ended	12 Months Ended										141 Months Ended
	Jul. 17, 2012	Jan. 31, 2011	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Mar. 31, 2001	Dec. 31, 2006	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Mar. 31, 2006	Mar. 31, 2005	Mar. 31, 2004	Mar. 31, 2003	Mar. 31, 2002	Jun. 30, 2012		May 21, 2004
Common stock, shares issued			128,586,644		128,586,644				126,444,309										128,586,644		10,238,000
Common stock, shares outstanding			128,586,644		128,586,644				126,444,309										128,586,644		10,238,000
Net loss			$ 830	$ 1,097	$ 1,702	$ 1,802	$ (17)	$ (3,924)	$ (3,918)	$ (2,419)	$ (1,781)	$ (3,472)	$ (6,244)	$ (3,317)	$ (18,840)	$ (73)	$ (47)	$ (26)	$ 45,780	[1]
Deficit accumulated during the development stage			45,780		45,780				44,078										45,780
Proceeds From Issuance Of Common Stock Gross	5,700
Common Stock Transferred As Per Purchase Agreement																					6,880,000
Stock Issued During Period, Value, New Issues	$ 4,900	$ 235								$ 400
Purchase Agreement [Member]
Common stock, shares issued																					10,238,000
Common stock, shares outstanding																					10,238,000

[1] Out of the which, cash flows used in discontinued operating activities of $36, cash flows used in discontinued investing activities of $16 and cash flows provided in discontinued financing activities of $57, relating to the period from inception to March 31, 2004, is unaudited.

XML

STOCK CAPITAL (Details 2) (USD $)	1 Months Ended		6 Months Ended	12 Months Ended
	Jul. 31, 2012	Apr. 30, 2012	Jun. 30, 2012	Dec. 31, 2004
Number of warrants issued		166,666	166,666
Options,Exercised		483,333	(1,182,606)
Exercise Price	$ 0.348			$ 0.01
Number Of Warrants Issued Total			78,637,499
Warrant Exercised Total			16,468,540
Warrant Forfeited Total			14,586,794
Warrants Outstanding Total			47,582,165
Warrants Exercisable Total			46,548,831
Issuance Date Nov 2004 [Member]
Number of warrants issued			12,800,845
Options,Exercised			12,596,010
Forfeited			204,835
Outstanding			0
Exercise Price			0.01
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Dec 2004 [Member]
Number of warrants issued			1,800,000
Options,Exercised			1,800,000
Outstanding			0
Exercise Price			0.00005
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Feb 2005 [Member]
Number of warrants issued			1,894,808
Forfeited			1,894,808
Outstanding			0
Exercise Price			2.5
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date May 2005 [Member]
Number of warrants issued			47,500
Forfeited			47,500
Outstanding			0
Exercise Price			1.62
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Jun 2005 [Member]
Number of warrants issued			30,000
Outstanding			30,000
Exercise Price			0.75
Warrants exercisable			30,000
Warrant Exercisable Term			Jun-15
Issuance Date Aug 2005 [Member]
Number of warrants issued			70,000
Forfeited			70,000
Outstanding			0
Exercise Price			0.15
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Sep 2005 [Member]
Number of warrants issued			3,000
Options,Exercised			3,000
Outstanding			0
Exercise Price			0.15
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Sep 2005 One [Member]
Number of warrants issued			36,000
Forfeited			36,000
Outstanding			0
Exercise Price			0.75
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Sep - Dec 2005 [Member]
Number of warrants issued			500,000
Forfeited			500,000
Outstanding			0
Exercise Price			1
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Dec 2005 [Member]
Number of warrants issued			477,163
Options,Exercised			170,000
Outstanding			307,163
Exercise Price			0.15
Warrants exercisable			307,163
Warrant Exercisable Term			December 2015
Issuance Date Feb 2006 [Member]
Number of warrants issued			230,000
Outstanding			230,000
Exercise Price			0.65
Warrants exercisable			230,000
Warrant Exercisable Term			Feb-16
Issuance Date Feb 2006 One [Member]
Number of warrants issued			40,000
Forfeited			40,000
Outstanding			0
Exercise Price			1.5
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Feb 2006 Two [Member]
Number of warrants issued			8,000
Forfeited			8,000
Outstanding			0
Exercise Price			0.15
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Feb 2006 Three [Member]
Number of warrants issued			189,000
Options,Exercised			97,696
Forfeited			91,304
Outstanding			0
Exercise Price			0.5
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date May 2006 [Member]
Number of warrants issued			50,000
Outstanding			50,000
Exercise Price			0.0005
Warrants exercisable			50,000
Warrant Exercisable Term			May-16
Issuance Date May - Dec 2006 [Member]
Number of warrants issued			48,000
Forfeited			48,000
Outstanding			0
Exercise Price			0.35
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date May - Dec 2006 One [Member]
Number of warrants issued			48,000
Forfeited			48,000
Outstanding			0
Exercise Price			0.75
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date May 2006 One [Member]
Number of warrants issued			200,000
Outstanding			200,000
Exercise Price			1
Warrants exercisable			200,000
Warrant Exercisable Term			May-16
Issuance Date Jun 2006 [Member]
Number of warrants issued			24,000
Forfeited			24,000
Outstanding			0
Exercise Price			0.15
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date May 2006 Two [Member]
Number of warrants issued			19,355
Forfeited			19,355
Outstanding			0
Exercise Price			0.15
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Oct 2006 [Member]
Number of warrants issued			630,000
Options,Exercised			630,000
Outstanding			0
Exercise Price			0.3
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Dec 2006 [Member]
Number of warrants issued			200,000
Forfeited			200,000
Outstanding			0
Exercise Price			0.45
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Mar 2007 [Member]
Number of warrants issued			700,000
Forfeited			200,000
Outstanding			500,000
Exercise Price			0.47
Warrants exercisable			500,000
Warrant Exercisable Term			March 2017
Issuance Date Mar 2007 One [Member]
Number of warrants issued			65,000
Forfeited			65,000
Outstanding			0
Exercise Price			0.15
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Feb 2007 [Member]
Number of warrants issued			50,000
Forfeited			50,000
Outstanding			0
Exercise Price			0.45
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Mar 2007 [Member]
Number of warrants issued			275,000
Forfeited			275,000
Outstanding			0
Exercise Price			0.45
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Apr 2007 [Member]
Number of warrants issued			33,300
Forfeited			33,300
Outstanding			0
Exercise Price			0.45
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date May 2007 [Member]
Number of warrants issued			250,000
Forfeited			250,000
Outstanding			0
Exercise Price			0.45
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Jul 2007 [Member]
Number of warrants issued			500,000
Outstanding			500,000
Exercise Price			0.39
Warrants exercisable			500,000
Warrant Exercisable Term			Jul-17
Issuance Date Sep 2007 [Member]
Number of warrants issued			500,000
Outstanding			500,000
Exercise Price			0.15
Warrants exercisable			500,000
Warrant Exercisable Term			Aug-17
Issuance Date Aug 2007 [Member]
Number of warrants issued			7,562,500
Outstanding			7,562,500
Exercise Price			0.2
Warrants exercisable			7,562,500
Warrant Exercisable Term			Nov-13
Issuance Date July 2007 One [Member]
Number of warrants issued			130,000
Forfeited			130,000
Outstanding			0
Exercise Price			0.45
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Oct 2007 [Member]
Number of warrants issued			200,000
Outstanding			200,000
Exercise Price			0.15
Warrants exercisable			200,000
Warrant Exercisable Term			Oct-17
Issuance Date Nov 2007 [Member]
Number of warrants issued			2,520,833
Outstanding			2,520,833
Exercise Price			0.2
Warrants exercisable			2,520,833
Warrant Exercisable Term			Nov-13
Issuance Date Nov 2007 One [Member]
Number of warrants issued			2,016,667
Outstanding			2,016,667
Exercise Price			0.29
Warrants exercisable			2,016,667
Warrant Exercisable Term			Nov-13
Issuance Date Apr 2008 [Member]
Number of warrants issued			4,537,500
Outstanding			4,537,500
Exercise Price			0.29
Warrants exercisable			4,537,500
Warrant Exercisable Term			Nov-13
Issuance Date Aug 2008 [Member]
Number of warrants issued			3,529,166
Outstanding			3,529,166
Exercise Price			0.29
Warrants exercisable			3,529,166
Warrant Exercisable Term			Nov-13
Issuance Date Aug 2008 One [Member]
Number of warrants issued			1,008,334
Outstanding			1,008,334
Exercise Price			0.29
Warrants exercisable			1,008,333
Warrant Exercisable Term			Nov-13
Issuance Date Nov 2008 [Member]
Number of warrants issued			100,000
Outstanding			100,000
Exercise Price			0.15
Warrants exercisable			100,000
Warrant Exercisable Term			Sep-18
Issuance Date Apr 2009 [Member]
Number of warrants issued			200,000
Outstanding			200,000
Exercise Price			0.1
Warrants exercisable			200,000
Warrant Exercisable Term			Apr-19
Issuance Date Oct 2009 [Member]
Number of warrants issued			200,000
Options,Exercised			100,000
Outstanding			100,000
Exercise Price			0.067
Warrants exercisable			66,667
Warrant Exercisable Term			Oct-19
Issuance Date Oct 2009 One [Member]
Number of warrants issued			4,537,500
Outstanding			4,537,500
Exercise Price			0.29
Warrants exercisable			4,537,500
Warrant Exercisable Term			Nov-13
Issuance Date Jan 2010 [Member]
Number of warrants issued			1,250,000
Forfeited			1,250,000
Outstanding			0
Exercise Price			0.5
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Feb 2010 [Member]
Number of warrants issued			125,000
Options,Exercised			125,000
Outstanding			0
Exercise Price			0.01
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Feb 2010 One [Member]
Number of warrants issued			3,000,000
Forfeited			3,000,000
Outstanding			0
Exercise Price			0.5
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Jan 2011 [Member]
Number of warrants issued			4,537,500
Outstanding			4,537,500
Exercise Price			0.29
Warrants exercisable			4,537,500
Warrant Exercisable Term			Nov-13
Issuance Date Feb 2011 [Member]
Number of warrants issued			641,026
Forfeited			641,026
Outstanding			0
Exercise Price			0.39
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Feb 2011 One [Member]
Number of warrants issued			6,407,500
Options,Exercised			946,834
Forfeited			5,460,666
Outstanding			0
Exercise Price			0.28
Warrants exercisable			0
Warrant Exercisable Term			-
Issuance Date Feb 2011 Two [Member]
Number of warrants issued			12,815,000
Outstanding			12,815,000
Exercise Price			0.5
Warrants exercisable			12,815,000
Warrant Exercisable Term			Feb-13
Issuance Date Apr 2010 [Member]
Number of warrants issued			33,334
Outstanding			33,334
Exercise Price			0.00005
Warrants exercisable			33,334
Warrant Exercisable Term			Apr-20
Issuance Date Apr 2011 [Member]
Number of warrants issued			33,334
Outstanding			33,334
Exercise Price			0.00005
Warrants exercisable			33,334
Warrant Exercisable Term			Apr-21
Issuance Date Feb 2010 Two [Member]
Number of warrants issued			1,500,000
Outstanding			1,500,000
Exercise Price			0.00005
Warrants exercisable			500,000
Warrant Exercisable Term			Feb-20
Issuance Date Apr 2012 [Member]
Number of warrants issued			33,334
Outstanding			33,334
Exercise Price			0.00005
Warrants exercisable			33,334
Warrant Exercisable Term			April 2022

XML

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $) In Thousands, except Share data	Common Stock [Member]		Additional Paid-In Capital [Member]		Deferred Compensation, Share-Based Payments [Member]	Accumulated Deficit During Development Stage [Member]	Total
Balance at Sep. 22, 2000	$ 0		$ 0		$ 0	$ 0	$ 0
Stock issued on September 22, 2000 for cash at $0.00188 per share	1		16		0	0	17
Stock issued on September 22, 2000 for cash at $0.00188 per share (in shares)	8,500,000
Stock issued on June 30, 2001 for cash at $0.0375 per share	0	[1]	60		0	0	60
Stock issued on June 30, 2001 for cash at $0.0375 per share (in shares)	1,600,000
Contribution of capital	0		8		0	0	8
Net loss	0		0		0	(17)	(17)
Balance at Mar. 31, 2001	1		84		0	(17)	68
Balance (in shares) at Mar. 31, 2001	10,100,000
Contribution of capital	0		11		0	0	11
Net loss	0		0		0	(26)	(26)
Balance at Mar. 31, 2002	1		95		0	(43)	53
Balance (in shares) at Mar. 31, 2002	10,100,000
Contribution of capital	0		15		0	0	15
Net loss	0		0		0	(47)	(47)
Balance at Mar. 31, 2003	1		110		0	(90)	21
Balance (in shares) at Mar. 31, 2003	10,100,000
2-for-1 stock split	0	[1]	0		0	0	0
2-for-1 stock split (in shares)	10,100,000
Stock issued on August 31, 2003 to purchase mineral option at $0.065 per share	0	[1]	6		0	0	6
Stock issued on August 31, 2003 to purchase mineral option at $0.065 per share (in shares)	100,000
Cancellation of shares granted to service providers	0	[1]	0	[1]	0	0	0
Cancellation of shares granted to service providers (in shares)	(10,062,000)
Contribution of capital	0	[1]	15		0	0	15
Net loss	0		0		0	(73)	(73)
Balance at Mar. 31, 2004	1		131		0	(163)	(31)
Balance (in shares) at Mar. 31, 2004	10,238,000
Compensation related to shares and options granted to service providers	0	[1]	17,506		0	0	17,506
Compensation related to shares and options granted to service providers (in shares)	2,025,000
Deferred stock-based compensation related to options granted to employees	0		5,979		(5,979)	0	0
Cancellation of shares granted to service providers	0	[1]			0	0	0
Cancellation of shares granted to service providers (in shares)	(1,800,000)
Stock issued on June 24, 2004 for private placement at $0.01 per share, net of $25,000 issuance expenses	0	[1]	60		0	0	60
Stock issued on June 24, 2004 for private placement at $0.01 per share, net of $25,000 issuance expenses (in shares)	8,510,000
Contribution of capital	0		7		0	0	7
Stock issued for amendment of private placement	0	[1]	1,418		0	0	1,418
Stock issued for amendment of private placement (in shares)	1,894,808
Amortization of deferred stock-based compensation related to shares and options granted to employees	0		0		584	0	584
Net loss	0		0		0	(18,840)	(18,840)
Balance at Mar. 31, 2005	1		25,101		(5,395)	(19,003)	704
Balance (in shares) at Mar. 31, 2005	20,867,808
Compensation related to shares and options granted to service providers	0	[1]	662		0	0	662
Compensation related to shares and options granted to service providers (in shares)	934,904
Deferred stock-based compensation related to options granted to employees	0	[1]	486		(486)	0	0
Stock-based compensation related to shares and options granted to directors and employees (in shares)	200,000
Amortization of deferred stock-based compensation related to shares and options granted to employees	0		51		1,123	0	1,174
Stock issued on May 12, 2005 for private placement at $0.80 per share	0	[1]	149		0	0	149
Stock issued on May 12, 2005 for private placement at $0.80 per share (in shares)	186,875
Stock issued on July 27, 2005 for private placement at $0.60 per share	0	[1]	99		0	0	99
Stock issued on July 27, 2005 for private placement at $0.60 per share (in shares)	165,000
Stock issued on September 30, 2005 for private placement at $0.80 per share	0	[1]	225		0	0	225
Stock issued on September 30, 2005 for private placement at $0.80 per share (in shares)	312,500
Stock issued on December 7, 2005 for private placement at $0.80 per share	0	[1]	135		0	0	135
Stock issued on December 7, 2005 for private placement at $0.80 per share (in shares)	187,500
Forfeiture of options granted to employees	0		(3,363)		3,363	0	0
Reclassification due to application of ASC 815-40-25 (formerly EITF 00-19)	0		(7,906)				(7,906)
Beneficial conversion feature related to convertible loans	0		164		0	0	164
Net loss	0		0		0	(3,317)	(3,317)
Balance at Mar. 31, 2006	1		15,803		(1,395)	(22,320)	(7,911)
Balance (in shares) at Mar. 31, 2006	22,854,587
Compensation related to shares and options granted to service providers	0		453		0	0	453
Compensation related to shares and options granted to service providers (in shares)	1,147,225
Deferred stock-based compensation related to options granted to employees	0	[1]	1,168		0	0	1,168
Stock-based compensation related to shares and options granted to directors and employees (in shares)	200,000
Reclassification due to application of ASC 815-40-25 (formerly EITF 00-19)	0		7,191		0	0	7,191
Beneficial conversion feature related to convertible loans	0		1,086		0	0	1,086
Elimination of deferred stock compensation due to implementation of ASC 718-10 (formerly SFAS 123(R)	0		(1,395)		1,395	0	0
Warrants issued to convertible note holder	0		11		0	0	11
Warrants issued to loan holder	0		110		0	0	110
Net loss	0		0		0	(3,924)	(3,924)
Balance at Dec. 31, 2006	1		24,427		0	(26,244)	(1,816)
Balance (in shares) at Dec. 31, 2006	24,201,812
Compensation related to shares and options granted to service providers			1,446		0	0	1,446
Compensation related to shares and options granted to service providers (in shares)	544,095
Deferred stock-based compensation related to options granted to employees	0	[1]	1,232		0	0	1,232
Stock-based compensation related to shares and options granted to directors and employees (in shares)	200,000
Exercise of warrants	0	[1]	214		0	0	214
Exercise of warrants (in shares)	3,832,621
Stock issued for amendment of private placement	1		1,999		0	0	2,000
Stock issued for amendment of private placement (in shares)	11,500,000
Beneficial conversion feature related to convertible loans	0		407		0	0	407
Warrants issued to convertible note holder	0		109		0	0	109
Conversion of convertible loans	0	[1]	224		0	0	224
Conversion of convertible loans (in shares)	725,881
Net loss	0		0		0	(6,244)	(6,244)
Balance at Dec. 31, 2007	2		30,058		0	(32,488)	(2,428)
Balance (in shares) at Dec. 31, 2007	41,004,409
Compensation related to shares and options granted to service providers	0		33		0	0	33
Compensation related to shares and options granted to service providers (in shares)	90,000
Deferred stock-based compensation related to options granted to employees	0		731		0	0	731
Exercise of options	0	[1]	3		0	0	3
Exercise of options (in shares)	17,399
Exercise of warrants	0	[1]	0		0	0	0
Exercise of warrants (in shares)	1,860,000
Stock issued for amendment of private placement	1		1,499		0	0	1,500
Stock issued for amendment of private placement (in shares)	8,625,000
Conversion of convertible loans	0	[1]	1,276		0	0	1,276
Conversion of convertible loans (in shares)	3,644,610
Subscription of shares for private placement	0		281		0	0	281
Net loss	0		0		0	(3,472)	(3,472)
Balance at Dec. 31, 2008	3		33,881		0	(35,960)	(2,076)
Balance (in shares) at Dec. 31, 2008	55,241,418
Compensation related to shares and options granted to service providers	0	[1]	775		0	0	775
Compensation related to shares and options granted to service providers (in shares)	5,284,284
Deferred stock-based compensation related to options granted to employees	0		409		0	0	409
Exercise of warrants	0	[1]	0		0	0	0
Exercise of warrants (in shares)	3,366,783
Stock issued for amendment of private placement	1		0		0	0	1
Stock issued for amendment of private placement (in shares)	9,916,667
Conversion of convertible loans	0	[1]	200		0	0	200
Conversion of convertible loans (in shares)	2,500,000
Subscription of shares for private placement	0		729		0	0	729
Net loss	0		0		0	(1,781)	(1,781)
Balance at Dec. 31, 2009	4		35,994		0	(37,741)	(1,743)
Balance (in shares) at Dec. 31, 2009	76,309,152
Compensation related to shares and options granted to service providers	0	[1]	96		0	0	96
Compensation related to shares and options granted to service providers (in shares)	443,333
Deferred stock-based compensation related to options granted to employees	0	[1]	388		0	0	388
Stock-based compensation related to shares and options granted to directors and employees (in shares)	466,667
Conversion of convertible note	0	[1]	135		0	0	135
Conversion of convertible note (in shares)	402,385
Exercise of options	0	[1]	77		0	0	77
Exercise of options (in shares)	1,540,885
Exercise of warrants	0	[1]	11		0	0	11
Exercise of warrants (in shares)	3,929,446
Issuance of shares on account of previously subscribed shares	0	[1]	0		0	0	0
Issuance of shares on account of previously subscribed shares (in shares)	2,000,001
Stock issued for amendment of private placement	1		1,750		0	0	1,751
Stock issued for amendment of private placement (in shares)	7,250,000
Conversion of convertible loans	0	[1]	189		0	0	189
Conversion of convertible loans (in shares)	1,016,109
Issuance of shares			400				400
Issuance of shares (in shares)	2,475,000
Conversion of trade payable to stock			201				201
Subscription of shares for private placement			455		0	0	455
Net loss	0		0		0	(2,419)	(2,419)
Balance at Dec. 31, 2010	5		39,696		0	(40,160)	(459)
Balance (in shares) at Dec. 31, 2010	95,832,978
Compensation related to shares and options granted to service providers	0		449		0	0	449
Compensation related to shares and options granted to service providers (in shares)	474,203
Deferred stock-based compensation related to options granted to employees	0		1,135		0	0	1,135
Stock-based compensation related to shares and options granted to directors and employees (in shares)	2,025,040
Conversion of convertible note	0		140		0	0	140
Conversion of convertible note (in shares)	755,594
Exercise of options	0		243		0	0	243
Exercise of options (in shares)	1,648,728
Exercise of warrants	0		272		0	0	272
Exercise of warrants (in shares)	1,046,834
Issuance of shares for private placement	1		3,601		0	0	3,602
Issuance of shares for private placement (in shares)	14,160,933
Issuance of shares on account of previously subscribed shares	0		24		0	0	24
Issuance of shares on account of previously subscribed shares (in shares)	10,499,999
Issuance of shares (in shares)							309,977
Net loss	0		0		0	(3,918)	(3,918)
Balance at Dec. 31, 2011	6		45,560		0	(44,078)	1,488
Balance (in shares) at Dec. 31, 2011	126,444,309
Compensation related to shares and options granted to service providers	0		8		0	0	8
Compensation related to shares and options granted to service providers (in shares)	0
Stock-based compensation related to stock and options granted to directors and employees			313				313
Exercise of options	0		137		0		137
Exercise of options (in shares)	1,182,606						(1,182,606)
Exercise of warrants	0		9	[1]	0		9	[1]
Exercise of warrants (in shares)	959,729
Net loss	0		0		0	(1,702)	1,702
Balance at Jun. 30, 2012	$ 6		$ 46,027		$ 0	$ (45,780)	$ 253
Balance (in shares) at Jun. 30, 2012	128,586,644

[1] Represents an amount less than $1.

XML

UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

6 Months Ended

Jun. 30, 2012

Interim Consolidated Financial Statement Disclosure [Abstract]

Quarterly Financial Information [Text Block]

NOTE 3 - UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited interim financial statements have been prepared in a condensed format and include the consolidated financial operations of the Company and its wholly-owned subsidiary as of June 30, 2012 and for the three months then ended, in accordance with accounting principles generally accepted in the United States relating to the preparation of financial statements for interim periods. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2012, are not necessarily indicative of the results that may be expected for the year ended December 31, 2012.

XML

STOCK CAPITAL (Details 1) (USD $) In Thousands, except Share data, unless otherwise specified	1 Months Ended	6 Months Ended
	Apr. 30, 2012	Jun. 30, 2012	Sep. 30, 2011
Options,Outstanding at beginning of period		4,938,821
Options,Granted	166,666	166,666
Options,Exercised	483,333	(1,182,606)
Options, Reclassified		13,784
Options,Outstanding at end of period		3,936,665
Vested and expected-to-vest at end of period		3,204,999
Weighted average exercise price, Outstanding at beginning of period		$ 0.168	$ 0.168
Weighted average exercise price, Granted		$ 0.00005
Weighted average exercise price, Exercised		$ 0.116
Weighted Average Exercise Price, Reclassified		$ 0.010
Weighted average exercise price,Outstanding at end of period		$ 0.1766	$ 0.168
Weighted average exercise price, Vested and expected-to-vest at end of period		$ 0.1812
Aggregate intrinsic value,Outstanding at end of period		$ 407,051
Aggregate intrinsic value,Vested and expected-to-vest at end of period		$ 316,654